書籍詳細

chapter I 基礎

P.16 掲載の参考文献

• 1) Broze, G. J., Leykam, J. E., Schwartz, B. D. et al.:Purification of human brain tissue factor. J. Biol. Chem. 260:10917-10920, 1985
  pubmed

• 2) Morrissey, J. M., Fakhrai, H., Edgington, T. S. et al.:Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 50:129-135, 1987

• 3) Spicer, E. K., Morton, R., Bloem, L. et al.:Isolation of cDNA clones coding for human tissue factor:Primary structure of the protein and cDNA. Proc. Natl. Acad. Sci. USA 84:5148-5152, 1987

• 4) Scarpati, E. M., Wen, D., Broze, G. J. et al.:Human tissue factor:cDNA sequence and chromosome localization of the gene. Biochemistry 26:5234-5238, 1987
  pubmed

• 5) Fisher, K., Gorman, C., Vehar, G. et al.:Cloning and expression of human tissue factor cDNA. Thromb. Res. 48:89-99, 1987
  pubmed

• 6) Takayenoki, Y., Muta, T., Miyata, T. et al.:cDNA and amino acid sequence of bovine tissue factor. Biochem. Biophys. Res. Commun. 181:1145-1150, 1991
  pubmed

• 7) Shigematsu, Y., Miyata, T., Higashi, S. et al.:Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa. J. Biol. Chem. 267:21329-21337, 1992
  pubmed

• 8) Ruf, W., Edgington, T. S.:Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor VIIa. Proc. Natl. Acad. Sci. USA 88:8430-8434, 1991
  pubmed

• 9) Ruf, W., Miles, D. J., Rehemtulla, A. et al.:Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J. Biol. Chem. 267:6375-6381, 1992
  pubmed

• 10) Edgington, T. S., Mackman, N., Brand, K. et al.:The structural biology of expression and function of tissue factor. Thromb. Haemost. 66:67-79, 1991
  pubmed

• 11) Wilcox, J. N., Smith, K. M., Schwartz, S. M. et al.:Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86:2839-2843, 1989

• 12) Drake, T. A., Morrissey, J. H., Edgington, T. S.:Selective cellular expression of tissue factor in human tissues. Implication for disorders of hemostasis and thrombosis. Am. J. Pathol. 134:1087-1097, 1989
  pubmed

• 13) Faulk, U. P., Labarrere, C. A., Carson, S. D.:Tissue factor:Identification and characterization of cell types in human placentae. Blood 76:86-96, 1990

• 14) 居石克夫:血管内皮細胞障害と動脈硬化. 血管と内皮 4:435-443, 1994

• 15) Stern, D. M., Bank, I., Nawroth, P. P. et al.:Self-regulation of procoagulant events on the endothelial cell surface. J. Exp. Med. 162:1223-1235, 1985

• 16) Weiss, H. J., Turitto, V. T., Baumgartner, H. R. et al.:Evidence for the presence of tissue factor activity on subendothelium. Blood 73:968-975, 1989
  pubmed

• 17) Ryan, J., Brett, J., Tijburg, P. et al.:Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80:966-974, 1992

• 18) Prpic, V., Weiel, J. E., Somers, S. D. et al.:Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidyl-inositol-4, 5-bisphosphate in murine peritoneal macrophages. J. Immunol. 139:526-533, 1987
  pubmed

• 19) Galdal, K. S., Lyberg, T., Evensen, S. A. et al.:Inhibition of the thromboplastin response of endothelial cell in vitro. Endothelial cells in vitro. Biochem. Pharmacol. 33:2723-2726, 1984
  pubmed

• 20) Lyberg, T.:Effect of cyclic AMP and cyclic GMP on thromboplastin (factor III) synthesis in human monocytes in vitro. Thromb. Haemost. 50:804-809, 1983
  pubmed

• 21) Nawroth, P. P., Bank, I., Handley, D. et al.:Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release to interleukin 1. J. Exp. Med. 163:1363-1375, 1986
  pubmed

• 22) Bevilacqua, M. P., Pober, J. S., Majeau, G. R. et al.:Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160:618-623, 1984
  pubmed

• 23) Nawroth, P. P., Stern, D. M.:Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740-745, 1986
  pubmed

• 24) 0sterud, B., Olsen, J. O., Benjaminsen, A. W.:The role of complement in the induction of thromboplastin synthesis. Haemostasis. 14:386-392, 1984

• 25) Bartha, K., Brisson, C., Archipoff, G. et al.:Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J. Biol. Chem. 268:421-429, 1993
  pubmed

• 26) Broze, G. J. Jr., Birarad, T. J., Novotny, W. F.:Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29:7539-7546, 1990

• 27) 武井明, 田代賀比古, 円城寺慶一ほか:Tissue Factor Pathway Inhitibor (TFPI) のヒト正常組織および腫瘍組織内局在に関する免疫組織化学的検討. 日病会誌 83:224, 1994

• 28) Broze, G. J. Jr., Warren, L. A., Girarad, J. J. et al.:Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatome) cells using bovine factor Xa affinity chromatography. Thoromb. Res. 48:253-259, 1987

• 29) Sandset, P. M., Warn-Cramer, B. J., Maki, S. L. et al.:Immuno-depletion of extrinsic pathway inhibitor sensitized rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78:1496-1502, 1991

• 30) Haskel, E. J., Torr, S. R., Day, K. C. et al.:Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 84:821-827, 1991
  pubmed

• 31) Uragoh, K., Sueishi, K., Nakamura, T. et al.:A novel immunohistochemical method for in vivo detection of endotoxin using horse shoe crab factor C. J. Histochem, Cytochem. 36:1275-1283, 1988

• 32) Takeuchi, M., Nakashima, Y., Miura, Y. et al.:The localization of lipopolysaccharide in an endotoxemic rat liver and its relation to sinusoidal thrombogenesis:Light and electron microscopic studies. Pathol. Res. Pract. 190:1123-1133, 1994

• 33) 市川晃治郎, 中川和憲, 居石克夫ほか:家兎 Shwartzman 反応における組織因子(TF)mRNAおよび蛋白発現に関する組織化学的検討. 日病会誌 83:224, 1994

• 34) Prydz, H., Allison, A. C.:Tissue thromboplastin activity of isolated human monocytes. Thromb. Haemost. 39:582-589, 1978
  pubmed

• 35) Brozna, J. P., Carson, S. D.:Monocyte-associated tissue factor is suppressed by phorbol myristate acetate. Blood 72:456-462, 1988
  pubmed

• 36) Ichikawa, K., Nakagawa, K., Hirano, K. et al.:The localization of tissue factor and apolipoprotein (a) in atherosclerotic lesions of the human aorta and their relation to fibrinogenfibrin transition. Pathol. Res. Pract. (in press)

• 37) Kohler, G., Milnstein, C.:Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
  pubmed

• 38) Schuff-Werner, P., Glaus, G., Armstrong, V. W. et al.:Enhanced procoagulant activity (PCA) of human monocyte/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis 78:109-112, 1989

• 39) Lesnik, P., Rouis, M., Skarlatos; S. et al.:Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 89:10370-10374, 1992
  pubmed

• 40) Taubman, M. B.:Gene induction in vessel wall injury. Thromb. Haemost. 70:180-183, 1993
  pubmed

• 41) Berg, K., Dahlen, G., Frick, M. H.:Lp (a) lipoprotein and prebeta 1-lipoprotein in patients with coronary heart disease, J. Clin. Genet. 6:230-235, 1974

• 42) Kostner, G. M., Avogara, P., Cazzolato, G. et al.:Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis 38:51-68, 1981

• 43) Koltringer, P., Jurgens, G.:A dominant role of lipoprotein (a) in the investigation and elevation parameters indicating the development of cervical atherosclerosis. Atherosclerosis 58:187-198, 1985
  pubmed

• 44) Scanu, A. M.:Lipoprotein (a) . A potential bridge between the fields of atherosclerosis and thrombosis. Arch. Pathol. Lab. Med. 112:1045-1047, 1988
  pubmed

• 45) Collen, D., Juhan-Vague, I.:Fibrinolysis and atherosclerosis. Semin. Thromb. Hemost. 14:180-183, 1988
  pubmed

• 46) Meade, T. W., Brozovic, M., Chakrabarti, R. R. et al.:Haemostatic function and ischemic heart disease:Principal results of the Northwick Park heart study. Lancet ii:533-537, 1986

• 47) Stone, M. C., Thorp, J. M.:Plasma fibrinogen-a major coronary risk factor. J. R. Coll. Gen. Pract. 35:565-569, 1985

• 48) Wilhelmsen, L, Svardsudd, K., Korsan-Bengtsen, K. et al.:Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311:501-505, 1984
  pubmed

• 49) Kannel, W. B., D:Agostin, R. B., Belanger, A. J.:Fibrinogen, cigarette smoking, and risk of cardiovascular disease:Insights from the Framingham study. Am. Heart J. 113:1006-1010, 1987

• 50) Tanaka, K., Sueishi, K.:The coagulation and fibrinolysis systems and atherosclerosis. Lab. Invest. 69:5-18, 1993
  pubmed

• 51) Almus, F. E., Rao, V. M., Fleck, R. A. et al.:Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 76:354-360, 1990

• 52) Juhan-Vague, I., Alessi, M. C.:Plasminogen activator inhibitor 1 and atherosclerosis. Thromb. Haemost. 70:138-143, 1993

• 53) Nelken, N. A., Soifer, S. J., O'Keefe, J. et al.:Thrombin receptor expression in normal and atherosclerotic human arteries. J. Clin. Invest. 90:1614-1621, 1992
  pubmed

P.30 掲載の参考文献

• 1) McIntire, L. V.:Bioengineering and vascular biology. Ann. Biomed. Eng. 221:2, 1994

• 2) Scheef, R. R. et al.:Cytokine activation of vascular endothelium. J. Biol. Chem. 263:5797, 1988

• 3) Kawai, Y. et al.:Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Blood 87:2314, 1996
  pubmed

• 4) Dahlback, B. et al.:Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc. Natl. Acad. Sci. USA 90:1004, 1993
  pubmed

• 5) Moake, J.L. et al.:Involvement of large plasma vWF multimers and unusually large multimer vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J. Clin. Invest. 78:1456, 1986
  pubmed

• 6) Murata, M. et al.:Platelet adhesion to thrombin-treated human endothelial cells. In:Microcirculation-An update Vol 1.(ed:Tsuchiya, M.), Excepta Medica, 1987, p.587

• 7) Ikeda, Y. et al.:Von Willebrand factor-dependent shear-induced platelet aggregation-basic mechanism and clinical implications. Ann. N.Y. Acad. Sci.:1996(in press)

• 8) Alevriadou, B. R. et al.:Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 87:1263, 1993

• 9) Weiss, H. J. et al.:Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by GPIIb/IIIa complex. J. Clin. Invest. 83:288, 1989
  pubmed

• 10) Libby, P.:Molecular bases of the acute coronary syndromes. Circulation 91:2844, 1995
  pubmed

• 11) Badimon, L. et al.:Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Arteriosclerosis 5:366, 1985
  pubmed

• 12) Strony, J. et al.:Aurintricarboxylic acid in canine model of coronary artery thrombosis. Circulation 81:1106, 1990
  pubmed

• 13) Ruggeri, Z.M.:The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Thromb. Haemost 74:460, 1995
  pubmed

• 14) Ikeda, Y. et al.:The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest. 87:1234, 1991
  pubmed

• 15) O'Brien, J. R.:Shear-induced platelet aggregation. Lancet 335:711, 1990
  pubmed

• 16) Ikeda, Y. et al.:Transmembrane calcium associated with von Willebrand factor binding to GP1b in the initiation of shear-induced platelet aggregation. Thromb. Haemost. 69:492, 1992

• 17) Oda, A. et al.:Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood:1996(in press)

• 18) Halushka, P. V. et al.:Thromboxane, prostaglandin and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol. 10:213, 1989

• 19) 西川政勝:Ca++ 代謝とcyclic AMP. 止血 血栓 線溶. 中外医学社, 1994, p.71

• 20) 富田敏行:第VII因子 組織因子 リン脂質. 止血 血栓 線溶. 中外医学社, 1994, p. 131

• 21) Petersen, T.E. et al.:The physiological inhibitors of blood coagulation and fibrinolysis. (ed:Collen, D. et al), Elsevier, 1979, p.43

• 22) Stenflo, J.:Protein C and related proteins. (ed:Bertina, R. C.), Churchill Livingstone, 1988, p.21

• 23) Dahlback, B.:Protein S and C4b-binding proteins. Thromb. Haemost. 66:46, 1991

• 24) Lindahl, A.K. et al.:The present status of tissue factor pathway inhibitor. Blood Coagul. Fi-brinolysis. 3:439, 1992

P.48 掲載の参考文献

• 1) Pober, J. S., Cotran, R. S.:Cytokines and endothelial cell biology. Physiol. Rev. 70:427-451, 1990
  pubmed

• 2) Nawroth, P. P., Handley, D. A., Esmon, C. T. et al.:Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc. Natl. Acad. Sci. USA 83:3460-3464, 1986
  pubmed

• 3) Scarpati, E. M., Sadler, J. E.:Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J. Biol. Chem. 264:20705-20713, 1989
  pubmed

• 4) Schleef, R. R., Bevilacqua, M. P., Sawdey, M. et al.:Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263:5797-5803, 1988
  pubmed

• 5) Abumiya, T., Nakamura, S., Takenaka, A. et al.:Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler. Thromb. 14:483-488, 1994
  pubmed

• 6) Weis, J. R., Pitas, R. E., Wilson, B. D. et al.:Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5:2459-2465, 1991
  pubmed

• 7) Fei, H., Berliner, J. A., Parhami, F. et al.:Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler. Thromb. 13:1711-1717, 1993
  pubmed

• 8) Kugiyama, K., Sakamoto, T., Misumi, S. et al.:Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ. Res. 73:335-343, 1993

• 9) Horie, S., Ishii, H., Kazama, M.:Enhancement of thrombin-thrombomodulin-catalysed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids:possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem. J. 301:683-691, 1994
  pubmed

• 10) Freyssinet, J. M., Wiesel, M. L., Gauchy, J. et al.:An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity-a mechanism for thrombosis. Thromb. Haemost. 55:309-313, 1986
  pubmed

• 11) Lentz, S. R., Sadsler, J. E.:Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J. Clin. Invest. 88:1906-1914, 1991

• 12) Nishinaga, M., Ozawa, T., Shimada, K.:Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J. Clin. Invest. 92:1381-1386, 1993
  pubmed

• 13) Vu, T. K., Hung, D. T., Wheaton, V. I. et al.:Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068, 1991
  pubmed

• 14) Ishii, H., Nakano, M., Tsubouchi, J. et al.:Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb. Haemost. 63:157-162, 1990
  pubmed

• 15) Dahlback, B., Carlsson, M., Svensson, P. J.:Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:prediction of a cofactor to activated protein C. Proc. Natl. Acad, Sci. USA 90:1004-1008, 1993
  pubmed

• 16) Hirokawa, K., Aoki, N.:Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J. Biochem. 108:839-845, 1990
  pubmed

• 17) Ishii, H., Kizaki, K., Uchiyama, H. et al.:Cyclic AMP increases thrombomodulin expression on membrane surface of cultured human umbilical vein endothelial cells. Thromb. Res. 59:841-850, 1990
  pubmed

• 18) Horie, S., Kizaki, K., Ishii, H. et al.:Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells. Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP. Biochem. J. 281:149-154, 1992
  pubmed

• 19) Ishii, H., Horie, S., Kizaki, K. et al.:Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 80:2556-2562, 1992
  pubmed

• 20) Kizaki, K., Ishii, H., Horie, S. et al.:Thrombomodulin induction by all-trans retinoic acid is independent of HL-60 cells differentiation to neutrophilic cells. Thromb. Haemost. 72:573-577, 1994
  pubmed

• 21) Koyama, T., Hirosawa, S., Kawamata, N. et al.:All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells:distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 84:3001-3009, 1994
  pubmed

• 22) Kapiotis, S., Besemer, J., Bevec, D. et. al.:Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood 78:410-415, 1991

P.70 掲載の参考文献

• 1) 高松純樹:先天性血栓性素因. Pharma Medica 11:37-40, 1993

• 2) Pabinger, I., Brucker, S., Kyrle, P. A. et al.:Hereditary deficiency of antithrombin III, protein C and protein S:Prevalence in patients with a history of venous thrombosis and criteria rational screening. Blood Coagul. Fibrinolysis 3:547, 1992
  pubmed

• 3) 高松純樹, 利見和夫, 山本晃士ほか:確定した深部静脈血栓症に於ける先天性凝固線溶因子欠乏・異常症 日本血栓止血学会誌 2:384, 1991

• 4) Dahlback, B., carlsson, M., Svensson, P. J.:Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90:1004, 1993
  pubmed

• 5) Halbmayer, W. M., Haushofer, A., Schon, R. et al.:The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul. Fibrinolysis 5:51, 1994
  pubmed

• 6) Griffin, J. H., Evatt, B., Wideman, C. et al.:Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989, 1993
  pubmed

• 7) Koster, T., Rosendaal, F. R., de Ronde, H. et al.:Venous thrombosis due to poor anticoagulant response to activated protein C:Leiden Thrombophilia Study. Lancet 342:1503, 1993
  pubmed

• 8) Svensson, P. J., Dahlback, B.:Resistance to activated protein C as a basis for venous thrombosis.N. Engl. J. Med. 330:517, 1994
  pubmed

• 9) Meade, T. W., Dyer, S., Howarth, D. J. et al.:Antithrombin III and procoagulant activity;sex differences and effects of the menopause. Br. J. Haematol 74:77, 1990
  pubmed

• 10) Tait, R. C., Walker, I. D., Perry, D. J.:Antithrombin III activity in healthy blood donors:Age andsex related changes and the prevalence of asymptomatic deficiency (letter) . Br. J. Haematol. 75:141, 1990

• 11) Wu, S., Seino, S., Bell, G. I.:Human antithrombin III gene length polymorphism revealed by the polymerase chain reaction. Nucl. Acids Res. 17:6433, 1989
  pubmed

• 12) 高松純樹:先天性アンチトロンビンIII欠乏症・異常症-遺伝子解析で明らかになったこと-. 血液腫瘍科 28:279-284, 1994

• 13) Miletich, J., Sherman, L, Broze, G.:Absence of thrombosis in subjects with heterozygous protein C deficiency. N. Engl. J. Med. 317:991, 1987
  pubmed

• 14) te Lintel Hekkert, W., Bertina, R. M., Restima, P. H.:Two RFLPS-7kb5'of the human protein C gene. Nucl. Acids Res. 16:11849, 1988

• 15) Yamamoto, K., Tanimoto, M., Matsushita, M. et al.:Genotype establishments for protein C deficiency by use of a DNA polymorphism in the gene. Blood 77:2633-2636, 1991

• 16) Yamamoto, K., Takamatsu, J., Saito, H.:Two novel sequence polymorphisms of the human protein C gene. Nucl. Acids Res. 19:6973, 1991

• 17) Reitsma, P. H., Poort, S. R., Bernard, F. et al.:Protein C deficiency:A data base of mutations Thromb. Haemost. 69:77, 1993

• 18) Gandrille, S., Alhenc-Gelas, M., Gaussem, P. et al.:Five novel mutations located in exon III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood 82:159, 1993

• 19) Yamamoto, K., Tanimoto, M., Matsushita, M. et al.:Impaired secretin of the elongated mutant of protein C (Protein C-Nagaya) Molecular and cellular basis for hereditary Protein C deficiency. J. Clin. Invest. 90:2439, 1992

• 20) Varumm, B. C., Young, C, Elliott, G. et al.:Axl receptor tyrosin kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373:623, 1995

• 21) Nakano, T., Higashino, K., Kikuchi, N. et al.:Vascular smooth muscle cell-derived, Gla-contain-ing growth-potentiating factor for Ca2+-mobilizing growth factors. J. Biol. Chem. 270:5702, 1995

• 22) Bona, R. D., Weinstein, R. E., Walker, F. J.:Pseudo protein S deficiency due to a defect in C4Bp. Blood 76:500a, 1990 (Abstract)

• 23) Comp, P. C., Forristall, J., West, C. D. et al.:Free protein S levels are elevated in familial C4Bp deficiency. Blood 76:2527, 1990

• 24) Ichinose, A., Espling, E. S., Takamatsu, J. et al.:Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. Proc. Natl. Acad. Sci. USA 88:115, 1991
  pubmed

• 25) Bertina, R. M., Koeleman, B. P. C., Koster, T. et al.:Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994

• 26) Girolami, A., Simioni, P., Scarano, L.:Evaluation of activated protein C resistance in stored plasma. Lancet 343:1288, 1994 (letter)
  pubmed

• 27) Visentin, G. P., Ford, S. E., Scott, J. P. et al.:Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cell. J. Clin. Invest. 93:81, 1994
  pubmed

• 28) Warkentin, T. E., Levine, M. N., Hirsh, J. et al.:Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1330, 1995
  pubmed

P.82 掲載の参考文献

• 1) Grabowski, E. F., Friedman, L. I., Leonard, E. F.:Effects of shear rate on the diffusion and adhesion of blood platelets to a foreign surface. Ind. Eng. Chem. Fundam.11:224-232, 1972

• 2) Tangelder, G. J., Teirlinck, H. C., Slaaf, D. W.:Distribution of blood platelets flowing in arter-ioles.Am. J. Physiol. 248:H318-H323, 1985

• 3) Tangelder, G. J., Slaaf, D. W., Muijtjens, A. M. M. et al.:Velocity profiles of blood platelets and red blood cells flowing in arterioles of the rabbit mesentery. Circ. Res. 59:505-514, 1986

• 4) Baumgartner, H. R.:The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc. Res. 5:167-179, 1973
  pubmed

• 5) Turitto, V. T., Baumgartner, H. R.:Platelet interaction with subendothelium in flowing rabbit blood:Effect of blood shear rate. Microvasc. Res. 17:38-54, 1979
  pubmed

• 6) Turitto, V. T., Weiss, H. J., Baumgartner, H. R.:The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood. Microvasc. Res. 19:352-365, 1980

• 7) Sato, M., Ohshima, N.:Platelet thrombus induced in vivo by filtered light and fluorescent dye in mesenteric microvessels of the rat. Thromb. Res. 35:319-334, 1984
  pubmed

• 8) Sato, M., Ohshima, N.:Effect of wall shear rate on thrombogenesis in microvessels of the rat mesentery. Circ. Res. 66:941-949, 1990
  pubmed

• 9) Begent, N., Born, G. V. R.:Growth rate in vivo of platelet thrombi, produced by iontophoresis of ADP, as a function of mean blood flow velocity. Nature 227:926-930, 1970

• 10) Sato, M., Ohshima, N.:Hemodynamics at stenoses formed by growing platelet thrombi in mesenteric microvasculature of rat. Microvasc. Res. 31:66-76, 1986
  pubmed

• 11) Belval, T., Hellums, J. D., Solis, R. T.:The kinetics of platelet aggregation induced by fluidshearing stress. Microvasc. Res. 28:279-288, 1984
  pubmed

• 12) Ikeda, Y., Handa, M., Kawano, K. et al.:The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest. 87:1234-1240, 1991
  pubmed

• 13) Slack, S. M., Jennings, L. K., Turitto, V. T.:Platelet size distribution measurements as indicators of shear stress-induced platelet aggregation. Ann. Biomed. Eng. 22:653-659, 1994
  pubmed

• 14) Konstantopoulos, K., Wu, K. K., Udden, M. M. et al.:Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology 32:73-93, 1995
  pubmed

• 15) 佐藤正明:壁ずり応力による血管内皮細胞の形態と機能の変化. 病理と臨床 11:805-812, 1993

• 16) 佐藤正明, 片岡則之:血流と内皮細胞の物理的応答概論. 血管と内皮 4:9-18, 1994

• 17) Frangos, J. A., Eskin, S. G., McIntire, L. V. et al.:Flow effects on prostacyclin production. by cultured human endothelial cells. Science 227:1477-1479, 1985
  pubmed

• 18) Diamond, S. L., Eskin, S. G., McIntire, L. V.:Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 243:1483-1485, 1989
  pubmed

chapter II 治療総論

P.101 掲載の参考文献

• 1) Gent, M., Blakely, J. A., Easton, J. D. et al and the CATS group.:The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. . Lancet I:1215-1220, 1985

• 2) Hass, W. K, Easton, J. D. et al for the Ticlopidine-Aspirin Stroke Study Group.:A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N. Engl. J. Med. 321:501-507, 1989

• 3) Antiplatelet Trialists:Collaboration.:Collaborative overview of randomised trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106, 1994

• 4) Antiplatelet Trialists' Collaboration.:Collaborative overview of randomised trials of antiplatelet therapy-II:Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br. Med. J. 308:159-168, 1994
  pubmed

• 5) Hourani, S. M. 0., Cusack, N. J.:Pharmacological receptors on blood platelets. Pharmacol. Rev. 43:243-297, 1991

• 6) Lekstrom, J. A, Bell., W. R.:Aspirin in the prevention of thrombosis. Medicine 70:161-178, 1991
  pubmed

• 7) Steering Committee of the Physicians' Health Study Research Group:Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321:129-135, 1989

• 8) Pete, R., Cray, R. et al.:Randomized trial of prophylactic daily aspirin in British male doctor. Br. Med. J. 296:313-320, 1988

• 9) 西川政勝:血小板治療の現状. 抗血小板薬の現況にっいて. 治療 73:988-993, 1991

• 10) 蔵本淳, 青木延雄, 池田康夫ほか編:抗血小板療法の基礎と臨床, 金芳堂, 京都, 1993

• 11) UK-TIA Study Group:United Kingdom transient ischemic attack (UK-TIA) aspirin trial:final results. J.Neurol. Neurosurg. Psychiatry. 54:1044-1054, 1991

• 12) Willard, J. E., Lange, R. A. et al.:The use of aspirin in ischemic heart disease. N. Engl. J. Med. 327:175-181, 1992
  pubmed

• 13) 西丸雄也, 山口武典:抗血小板薬の功罪に関する共同研究. 脳卒中 14:9-17, 1992

• 14) Dyerberg, J., Bang, H. 0.:Haemostatic function and platelet polyunsaturated fatty acid in Eskimos. Lancet 2:433-435, 1979

• 15) Dyerberg, J., Bang, H. 0. et al.:Eicosapentaenoic acid and prevention of thrombosis and atheros-clerosis?Lancet 2:117-119, 1978

• 16) Bairati, I., Roy, I. et al.:Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 85:950-956, 1992

• 17) Beavo, J. A., Reifsnyder, D. H.:Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:150-155, 1990
  pubmed

• 18) Beavo, J. A., Conti, M. et al.:Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:399-405, 1994
  pubmed

• 19) 西川政勝, 豊田英樹:血小板刺激伝達系-Cyclic Nucleotide系による情報伝達の抑制. 血液腫瘍科 28:141-151, 1994

• 20) Hidaka, H., Hayashi, H. et al.:Selective inhibitor of plaltelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J. Exp. Pharmacol. Ther. 211:26-30, 1979

• 21) Kimura, Y., Tani, T. et al.:Effect of cilostazol on platelet aggregation and experimental thrombosis. Arznei,uttelfoeschung/Drug Res. 35:1144-1149, 1985

• 22) 豊田英樹, 西川政勝ほか:シロスタゾール. 現代医療 25:3737-3742, 1993

• 23) Nishikawa, M., Komada, F. et al.:Inhibition of platelet aggregation by the phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase. Cell. Signal. 4:453-463, 1992

• 24) 田中利男, 向井淳, 中充子:環状ヌクレオチッドホスフォジエステラーゼ阻害剤の分子心臓薬理学. 日薬理誌 100:249-258, 1992

• 25) Giles, H.:More selective ligands at eicosanoid receptor subtypes improve prospects in inflammatory and cardiovascular research. Trends Pharmacol. Sci. 11:301-304, 1990
  pubmed

• 26) Ruggeri, Z. M.:Receptor-specific antiplatelet therapy. Circulation 80:1920-1922, 1989
  pubmed

• 27) Nichols, A. J., Ruffolo, R. R. Jr. et al.:Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol. Sci. 13:413-417, 1992
  pubmed

• 28) 西川政勝:血小板活性化と凝集反応. 続生化学実験講座7 (日本生化学会編), 東京化学同人, 東京, 1986, p.707-714

• 29) 服部晃:抗血小板療法のstrategy-薬剤固定法と機能固定法-. 日本臨床 50:385-391, 1992

• 30) 佐藤金夫, 尾崎由基男ほか:散乱光を用いた血小板凝集能の評価. 現代医療 25:3828-3832, 1993

• 31) Ikeda, Y., Handa, M. et al.:The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest. 87:1234-1240, 1991
  pubmed

• 32) 池田康夫:ずり応力惹起血小板凝集. 現代医療 25:3823-3827, 1993

• 33) Uchiyama, S., Yamazaki, M. et al.:Shear-induced platelet aggregation in cerebral ischemia. Stroke 25:1547-1551, 1994
  pubmed

• 34) 井原章裕, 藤村欣吾:血栓性疾患の血小板系統検査. 総合臨床 41:2932-2940, 1992

• 35) Abrams, C. S., Shattil, S. J.:Immunological detection of activated platelets in clinical disorders. Thromb. Haemost. 65:467-473, 1991.

• 36) Watts, G. F., Lewis, B. et al.:Effects of coronary artery disease of lipid-liwering diet, or diet plus cholestyramine, in the ST. Thomas' Atherosclerosis Regression Study (STARS) . Lancet 339:563-569, 1992

• 37) Treasure, C. B., Klein, J. L. et al.:Benificial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl.J. Med. 332:481-487, 1995

• 38) Anderson, T. J., Meredith, I. T. et al.:The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:488-493, 1995

P.121 掲載の参考文献

• 1) Landefeld, C. S., Goldman, L.:Major bleeding in outpatients treated with warfarin:Incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87:144, 1989
  pubmed

• 2) Vigano, S., Mannucci, P. M., Solinas, S. et al.:Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br. J. Haematol. 57:213, 1984
  pubmed

• 3) Poller, L.:Progress in standardization in anticoagulant control. Hematol. Rev. 1:225, 1987

• 4) Loeliger, E. A.:ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb. Haemost 54:155, 1985

• 5) ACPP/NHLBI National conference on antithrombotic therapy. Chest 89 (Suppl):1989

• 6) Launbjerg, J., Egeblad, H., Heaf, J. et al.:Bleeding comlications to oral anticoagulant therapy:Multivalent analysis of 1010 treatment years in 551 out patients.J. Intern. Med. 229:351, 1991

• 7) Verhagen, H.:Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicoumarol or dicmacyl. Acta Med. Scand. 148:455, 1954

• 8) Koch-Weser, J., Sellers, D. M.:Drug interactions with oral anticoagulants. N. Engl. J. Med. 285:487, 1971

• 9) Hall, J. A. G., Pauli, R. M., Wilson, K. M.:Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med. 103:325, 1980

• 10) Glazier, R. L., Corwell, F. B.:Randomized prospective trial of continuous vs. intermittent heparin therapy. JAMA 236:1365, 1976

• 11) Hull, R. D., Raskob, G. E., Hirsh, J. et al.:Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximalvein thrombosis. N. Engl. J. Med. 315:1109, 1986
  pubmed

• 12) Basu, D., Gallus, A., Hirsh, J. et al.:A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N. Engl. J. Med. 287:324, 1972

• 13) Racanelli, A., Fareed, J., Walenga, J. M. et al.:Biochemical and pharmacologic studies on the protamine interactions with heparins, its fractions and fragments. Semin. Thromb. Hemost. 11:176, 1985
  pubmed

• 14) Cimo, P. 1.:Heparin-induced thrombocytopenia;association with a platelet aggregating factor and arterial thrombosis. Am. J. Hematol. 6:125, 1979

• 15) Cines, D. B.:Immune endothelial-cell injury in heparin associated thrombocytopenia. N. Engl. J. Med. 316:581, 1987
  pubmed

• 16) Stenflo, J., Fernlund, P., Egan, W. et al.:Vitamin K-dependent modification of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA 71:2730, 1974
  pubmed

• 17) Kelly, J. G., 0:Malley, K.:Clinical pharmacokinetics of oral anticoagulants. Clin. Pharmacokinet. 4:1, 1979

• 18) 0'Reilly, R., Rytand, D.:Resistance to warfarin due to unrecognized vitamin K supplementation.N. Engl. J. Med. 303:160, 1980

• 19) Rosenberg, R. D., Lam, L.:Correlation between structural and function of heparin. Proc. Natl. Acad. Sci. 76:1218, 1979
  pubmed

• 20) Rosenberg, R. D., Damus, P. S.:The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248:6490, 1973
  pubmed

• 21) Villanueva, G. B., Danishefsky, I.:Evidence for a heparin-induced conformational change in antithrombin III. Biochem. Biophys. Res. Commun. 74:803, 1977

• 22) Young, E., Prins, M., Levine, M. N. et al.:Heparin binding to plasma proteins, an important mechanism for heparin resistance. Th romb Haemost. 67:639, 1992

• 23) Holmer, E, Kurachi, K., Soderstrom, G.:The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor XIIa and kallikrein by abtithrombin. Biochem. J. 193:395, 1981
  pubmed

• 24) Carter, C. J., Kelton, J. G., Hirsh, J. et al.:The relationship between the hemorrhagic and antithrombotic properties of low-molecular-weight heparins and heparin. Blood 59:1239, 1982
  pubmed

• 25) Peterson, C. B., Morgan, W. T., Blackburn, M. N.:Histidinerich glycoprotein modulation of the anticoagulant activity of heparin. J. Biol. Chem. 262:7567, 1987
  pubmed

• 26) Tamura, Y.:Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim. Biophys. Acta 484:417, 1977
  pubmed

• 27) Aoyama, T.:Pharmacological studies of FUT-175, nafamostat mesilate I. Inhibition of protease activity in vitro and in vivo experiments. Jpn. J. Pharmacol. 35:203, 1984
  pubmed

• 28) 0kamoto, S.:Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem. Biophys. Res. Commun. 101:440, 1981

• 29) Menache, D., O' Malley, J., Schorr, J. et al.:Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75:33, 1990

• 30) Blauhut, B., Kramer, H., Vinazzer, H. et al.:Substitution of AT III in shock and DIC.:A randomized study. Thrombs. Res. 39:81, 1985

• 31) Schwardt, R., Bauer, K., Rosenberg, R. D. et al.:Clinical experience with antithrombin III concentrate of treatment to congenital and acquired deficiency of antithrombin. Am. J. Med. 87:53 S, 1989

• 32) van Dieijen, G., Tans, G., Rosing, J. et al.:The role of phospholipid and factor Villa in the activation of bovine factor V. J. Biol. Chem. 256:3433, 1981

• 33) Taylor, F. B., Chang, A., Esmon, C. T. et al.:Protein C prevents the coagulopathic and letheal effects of Escherichia coli infusion in the boboon. J. Clin. Invest. 79:918, 1987

• 34) Stocker, K., Barlow, G. N.:Characterization of defibrase. In:Akuelle Probleme in der Angiologie:defibrirung mit thrombinahnlichen Schlangengiftenzymen (vol. 26) (eds:Martin, M., Schoop, W) Stuttgart, Hunber Verlag, 1975, p. 45

• 35) Suzuki, K., Kusumoto, H., Hashimoto, S.:Isolation and characterization of thrombomodulin from bovine lung. Biochim. Biophys. Acta 882.:343, 1986
  pubmed

• 36) Esmon, C. T., Esmon, N. L, Harris, K. W.:Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J. Biol. Chem. 257:7944, 1982
  pubmed

• 37) Gomi, K., Zushi, M., Honda, G. et al.:Antithrombotic effect of recombinant human thrombomodulin on thrombin induced thromboembolism in mice. Blood 75:1396, 1990
  pubmed

• 38) Markwardt, K.:Biochemistry and pharmacology of hirudin. Hematology 7:255-269, 1988

• 39) Dodt, J., Seemuller, U., Maschler, R. et al.:The complex covalent structure of hirudin. Localisation of the disulfide bonds. Biol. Chem. Hoppe Seyler 366:379, 1985

• 40) Cannon, C. P., Maraganore, J. M., Loscalzo, J. et al.:Antithrombotic and anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am. J. Cardiol. 71:778, 1993
  pubmed

P.138 掲載の参考文献

• 1) 松尾理:血栓溶解療法の理論的アプローチ. t-PAとPro-UK (松尾理著), 学際企画, 東京, 1986, p. 71-74

• 2) 松尾理ほか:ウロキナーゼ療法の適応と効果判定. 日本医事新報 2867:26-30, 1979

• 3) Kagitani, H., Tagawa, M., Hatanaka, K. et al.:Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity. FEBS Lett. 189:143-149, 1985

• 4) Weening-Verlroeff, E. J. D. et al,:Involvement of asparatic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis. Protein Eng. 4:191-198, 1990

• 5) Hoylaerts, M. et al.:Kinetics of the activation of plasminogen activator. J. Biol. Chem. 257:2912-2919, 1982
  pubmed

• 6) Matsuo, 0. et al.:Effect of urokinase on fibrinolysis and fibrinogenolysis. Jpn. J. Physiol. 32:879-883, 1982

• 7) Matsuo, O. et al.:Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291:590-591, 1981
  pubmed

• 8) Yahara, H. et al.:Recombinant variants of tissue-type plasminogen activator containing amino acid substituion between position 37 and 42. Fibrinolysis 8:286-293, 1994

• 9) Bennet, W. F. et al.:High resolution analysis of functional determinants on human tissue-type plasminogen activator. J. Biol. Chem. 266:5191-5201, 1991

• 10) Madison, E. L, Goldsmith, E. J., Gerard, R. D. et al.:Serpin-resistant mutant of human tissue-type plasminogen activator. Nature 399:721, 1989

• 11) Ikenaka, Y. et al:Characterization of human tissue-type plasminogen activator variants with amino acid mutation in the kringle 1 domain. Blood Coagul. Fibrinolysis 3:381-387, 1992
  pubmed

• 12) Lijnen, H. R. et al.:Activation of plasminogen by pro-urokinase. I. Mechanism. J. Biol. Chem. 261:1253-1258, 1986
  pubmed

• 13) Bando, H. et al. . Thrombolytic effect of prourokinase in vitro. Fibrinolysis 1. 169-176, 1987

• 14) Kambara, H. et al.:Randomized, double-blided multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase(GE-0943), and intracoronary urokinase in patients with acute myocardial infarction. Circulation 78:899-905, 1988
  pubmed

• 15) Lijnen, H. R. et al.:On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J. Biol. Chem. 266:11826-11832, 1991
  pubmed

• 16) Okada, K. et al.:Effects of α2-plasmin inhibitor on plasminogen activation by staphylokinase/plasminogen complex. Thromb. Res. 76:211-220, 1994

• 17) Okada, K. et al.:Kinetic analysis of plasminogen activation by staphylokinase/plasminogen complex in the presence of fibrin. Th romb. Res. 76:181-191, 1994

• 18) Matsuo, 0. et al.:Thrombolytic properties of staphylokinase. Blood 76:925-929, 1990

• 19) Collen, D., De Cock, F., Stassen, J.-M.:Comparative Immunogenicity and Thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87:996-1006, 1993
  pubmed

• 20) Collen, D., De Werf, V.:Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 87:1850-1853, 1993

P.156 掲載の参考文献

• 1) Textbook of Interventional Cardiology 2nd Edition Topol EJ, WB Saundars Courp, 1994

• 2) Interventional Cardiovascular Medicine Principles and practice. Roubin, G. S., Califf, R. M., O'neil, W. W. Charchill Livingstone, 1994

• 3) Gruentzig, A. R., Senning, A., Siegenthaler, W. E.:Non-operative dilatation of coronary artery stenosis:percutaneous transluminal coronary angioplasty. N. Engl. J, Med. 301:61, 1979

• 4) ACC/AHA Task Force Report:Guidelines for Percutaneous Transluminal Coronary Angioplasty. J. Am. Coll. Cardiol. 12:529, 1988

• 5) Detre, K., Holubkov, R., Kelsey, S. et al.:Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. N. Engl. J. Med. 318:265, 1988
  pubmed

• 6) Detre, K., Holubkov, R., Kelsey, S. et al.:One-year follow-up results of the 1985-1986 National Heart, Lung, and `Blood Institute's percutaneous transluminal coronary angioplasty registry. Circulation 80:421, 1989
  pubmed

• 7) Kent, K. M., Cowley, M. J., Kelsey, C. F. et al.:Long term follow-up of the NHLBI-PTCA registry. Circulation 74:II-280, 1986

• 8) Holmes, D. R., Holubkov, R., Vliestra, R. E. et al.:Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986:The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J. Am. Coll. Cardiol. 12:1149, 1988

• 9) Detre, K. M., Holmes, D. R. Jr, Holubkov, R. et al.:Incidence and consequences of periprocedural occlusion. Circulation 82:739, 1990
  pubmed

• 10) de Feyter, P. J., van den Brand, M., Jaarman, G. et al.:Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 83:927, 1991

• 11) Ellis, S. G., Roubin, G. S., King, S. B. III. et al.:Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77:372, 1988

• 12) Ellis, S. G., Vandormael, M. G., Cowley, M. J. et al.:Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation 82:1193, 1990
  pubmed

• 13) O'Keefe, J. H., Rutherford, B. D., McConahay, D. R. et al.:Multivessel coronary angioplasty from 1980 to 1989:perioprocedural results and long-term outcome.J. Am. Coll. Cardiol. 16:1097, 1990

• 14) Parisi, A. F., Folland, E. D., Hartigan, P and the Veterans Affairs ACME Investigators:A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N. Engl. J. Med. 326:10, 1992

• 15) Weintraub, W. S., Jones, E. L., King, S. B. lll. et al.:Changing use of coronary angioplasty and coronary bypass surgery in the treatment of chronic coronary artery disease. Am.J. Cardiol. 65:183, 1990

• 16) Grines, C. L. Browne, K. F, Marco, J. et al.:A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 328:673-679, 1993

• 17) Gibbons, R. J., Holmes, D. R., Reeder, G. S. et al.:Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N. Engl. J. Med. 328:685-691, 1993
  pubmed

• 18) Nobuyoshi, M., Kimura, T., Nosaka, H. et al.:Restenosis after successful percutaneous transluminal coronary angioplasty:Serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol 12:616-623, 1988
  pubmed

• 19) Mark, D. B., Nelson, C. L, Califf, R. M. et al.:Coutinuing evolution of therapy for coronary artery disease;Initial results from the era of coronary angioplasty. Circulation 89:2015-2025, 1994
  pubmed

• 20) Baim, D. S., Hinohara, T., Holmes, D. et al.:for the US Directional Coronary Atherectomy Investigator Group. Results of directional coronary atherectomy during multicenter preapproval testing. Am. J. Cardiol. 72:6E-11E, 1993
  pubmed

• 21) Hinohara, T., Rowe, M. H., Robertson, G. C. et al.:Effect of lesion characteristics on outcome of directional coronary atherectomy. J. Am. Coll. Cardiol. 17:1112-1120, 1991
  pubmed

• 22) Hinohara, T., Robertson, G., Selmon, M. et al.:Restenosis after directional coronary atherectomy. J. Am. Coll. Cardiol. 20:623-632, 1992
  pubmed

• 23) Topol, E. J., Leya, F., Pinkerton, C. A. et al.:for the CAVEAT Study Group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N. Engl. J. Med. 329 (4):221-227, 1993

• 24) Adelmah, A. G., Cohen, E. A., Kimball, B. P. et al.:A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. N. Engl. J. Med. 329 (4):228-233, 1993

• 25) Holmes, D. R. Jr., Topol, E. J., Califf, R. M. et al.:A multicenter randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation 91 (7):1966-1974, 1995
  pubmed

• 26) Kuntz, R., Hinohara, T., Safian, R. et al.:Restenosis after directional coronary atherectomy, effects of luminal diameter and deep wall excision. Circulation 86:1394-1399, 1992
  pubmed

• 27) Kuntz, R., Hinohara, T., Robertson, G. et al.:Influence of vessel selection in the observed restenosis rate after endoluminal stenting or directional atherectomy. Am. J. Cardiol. 70:1101-1108, 1992
  pubmed

• 28) Kuntz, R., Safian, R., Levine, et al.:Novel approach to the analysis of restenosis after the use of three new coronary devices. J. Am. Coll. Cardiol. 19:1493-1499, 1992

• 29) Ellis, S. G., Popma, J. J., Buchbinder, M. et al.:Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotatinal atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 89 (2):882-892, 1994

• 30) Safian, R., Niazi, K., Strazeleski, M. et al.:Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 88 (3):961-968, 1993

• 31) Stertzer, S., Rosenblum, Shaw, R. et al.:Coronary rotational ablation:Initial experience in 302 procedures. J. Am. Coll. Cardiol. 21 (2):287-295, 1993
  pubmed

• 32) Warth, D. C., Leon, M. B., 0'Neill, W. et al.:Rotational atherectomy multicenter registry:acute results, complications and 6-month angiographic follow-up in 709 patients. J. Am. Coll. Cardiol. 24 (3):641-648, 1994

• 33) Safian, R. D., Grines, C. L, May, M. A. et al.:Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts. Circulation 89(1):302-312, 1994
  pubmed

• 34) Popma, J., Leon, M., Mintz, G. et al.:Results of coronary angioplasty using the transluminal extraction catheter. Am. J. Cardiol. 70(20):1526-1532, 1992
  pubmed

• 35) Bittl, J. A., Sanborn, T. A., Tcheng, J. E. et al.:Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. Am. J. Cardiol. 70 (20):1533-1539, 1992
  pubmed

• 36) Baumbach, A., Bittl, J. A., Fleck, E. et al:Acute complications of excimer laser coronary angioplasty:a detailed analysis of multicenter results. Coinvestigators of the U. S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries.J. Am. Coll. Cardiol. 23(6):1305-1313, 1994

• 37) Litvack, F., Eigler, N, Margolis, J. et al.:Percutaneous excimer laser coronary angioplasty:results in the first consecutive 3, 000 patients. The ELCA Investigators. J. Am. Coll. Cardiol. 23 (2):323-329, 1994

• 38) Leon, M., Wong, S.:Intracoronary stents-a breakthrough technology or just another small step?Circulation 89:1323-1327, 1994
  pubmed

• 39) Baim, D., Kent, K., King, S. et al.:Evaluating new devices-acute (in-hospital) results from the New Approaches to Coronary Intervention Registry. Circulation 89:471-481, 1994
  pubmed

• 40) Schatz, R., Baim, D., Leon, M. et al.:Clinical experience with the Palmaz-Schatz coronary stent. Inital results of a multicenter study. Circulation 83:148-161, 1991

• 41) Fishman, D., Leon, M., Baim, D. et al.:A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary disease. N. Engl. J. Med. 331:496-501, 1994

• 42) Serruys, P., De Jaegere, P., Kiemeneij, F. et al.:A comparison of ballloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331:489-495, 1994

• 43) George, B. S., Voorhees, W. D., 3rd, Roubin, G. S. et al.:Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty:clinical and angiographic outcomes. J. Am. Coll. Cardiol. 22 (1):135-143, 1993
  pubmed

P.172 掲載の参考文献

• 1) Fuster, V., Badimon, L. et al.:The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J. Med. 326:242-250, 1992

• 2) Ross, R.:The pathogenesis of atherosclerosis:aperspective for the 1990s. Nature 362:801-809, 1993

• 3) Carvalho, A. C. A., Colman, R. W. et al.:Platelet function in hyperlipidemia. N. Engl. J. Med. 290:434-438, 1974

• 4) Higashihara, M., Miura, N. et al.:The effect of low-density lipoprotein on platelet function. Acta Haematol. Jpn. 53:1630-1638, 1990

• 5) Higashihara, M. Kinoshita, M. et al.:The role of apo E in inhibitory effects of apo E-rich HDL on platelet function. FEBS Lett. 282:82, 1991
  pubmed

• 6) Inaba, Y., Yamada, N. et al.:Expression of M-CSF receptor encoded by c-fms on smooth muscle cells derived from atherosclerotic lesion. J. Biol. Chem. 267:5693-5699, 1992

• 7) Simpson, H. C. R., Mann, J. I. et al.:Hypertriglyceridemia and hypercoagulability. Lancet 9:786-789, 1983

• 8) Mehta, J., Mehta, P. et al.:Plasama tissue plasminogen activator inhibitor levels in coronary artery disease:correlation with age and serum triglyceride concentration. J. Am. Com. Cardiol. 9:263-268, 1987

• 9) Miles, L. A., Fless, G. M. et al.:A potential basis for the thrombotic risks associated with lipoprotein(a) . Nature 339:301-303, 1989
  pubmed

• 10) Edelberg, J. M., Pizzo, S. V. et al.:Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. Blood Coagul. Frbrinolysis 2:759-764, 1991

• 11) Utermann, G., Hoppichler, F. et al.:Defects in the low density receptor gene affect lipoprotein(a) levels:multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc. Natl. Acad. Sci. USA 86:4171-4174, 1989
  pubmed

• 12) Kojima, S., Harpel, P. C. et al.:Lipoprotein(a) inhibits the generation of transforming growth factor β:an endogenous inhibition of smooth muscle cell migration. J. Cell Biol. 113:1439-1445, 1991

• 13) Assmannand, G., Schulte, H.:Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience) . Am. J. Cardiol. 70:733-737, 1992

• 14) Lawn, R. M., Wade, D. P. et al.:Atherogenesis in transgenic mice expressing human apolipoprotein(a) . Nature 360:670-672, 1992
  pubmed

• 15) The Scandinavian Simvastatin Survival Study Group. "Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease;the Scandinavian Simvastatin Survival Study (4S)"Lancet 344:1383-1389, 1994

• 16) Watts, G. F., Lewis, B. et al.:Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestylamine, in the St Thomas' Atherosclerosis Regression Study (STARS) . Lancet 339:563-569, 1992

• 17) Brown, G., Albers, J. J. et al.:Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323:1289-1298, 1990
  pubmed

• 18) Shepherd, J., Cobbe, S. M. et al.:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1301-1307, 1995
  pubmed

• 19) Anderson, T. J., Meredith, I. T. et al.:The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:488-493, 1995

• 20) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the Second Report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 269:3015-3023, 1993

• 21) 寺本民生, 山田信博ほか:ニセリトロール (ペリシット) のLp (a) に対する効果. 動脈硬化 20:625-633, 1992

chapter III 治療各論

P.186 掲載の参考文献

• 1) ACC/AHA Task Force.:Guidelines for the early management of patients with acute myocardial infarction. Circzalation 82:664-707, 1990
  pubmed

• 2) 延吉正清, 中川義久:急性心筋梗塞. 治療の基本. Medicina 31:1411-1415, 1994

• 3) Gruppo Italiano per Io Studio della Streptochinasi nell' Infarcto Myocardico(GISSI).:Effective-ness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397-402, 1986

• 4) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.:Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2. Lancet 2:349-360, 1988
  pubmed

• 5) Wilcox, R. G., Olsen, C. G., Skene, A. M. et al.:Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction:Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2:525-530, 1988

• 6) AIMS Trial Study Group.:Effect of intravenous APSAC on mortality after acute myocardial infarction:preliminary report of a plcebo-controlled clinical trial. Lancet 30:545-549, 1988

• 7) Topol, E. J., Morris, D. C., Smalling, R. W. et al.:A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J. Am. Coll. Cardiol. 9:1205-1213, 1987
  pubmed

• 8) Anderson, J. L, Marshall, H. W., Askins, J. C. et al.:A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. Circulation 70:606-618, 1984
  pubmed

• 9) Chesebro, J. H., Knatterud, G., Roberts, R. et al.:Thrombolysis in Myocardial Infarction(TIMI)Trial, Phase I:A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142-154, 1987
  pubmed

• 10) Armstrong, P. W., Baigrie, R. S., Daly, P. A. et al.:Tissue plasminogen activator:Tronto (TPAT) Placebo-Controlled Trial in Acute Myocardial Infarction. J. Am. Coll. Cardiol. 13:1469-1476, 1989

• 11) Verstraete, M., Brower, R. W., Collen, D. et al.:Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarctin (ECSG-1). Lancet 1:965-969, 1985

• 12) TIMI:Special Report:Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I Findings. N. Engl. J. Med. 312:932-936, 1985

• 13) Stack, R. S., 0'Connor, C. M., Mark, D. B. et al.:Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous strepto-kinase. Circulation 77:151-161, 1988

• 14) PRIMI Trial Study Group:Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1:863-868, 1989

• 15) Versraete, M, Bory, M., Collen, D. et al.:Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1:842-847, 1985

• 16) Neuhause, K., Tebbe, U., Gottwik, M. et al.:Intravenous recombinant tissue plasminogen activator(rt-PA) and urokinase in acute myocardial infarction:Results of the German Activator Urokinase Study (GAUS) . J. Am. Coll. Cardiol. 12:581-587, 1988

• 17) Califf, R. M., Topol, E. J., Stack, R. S. et al.:Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction:Results of Thrombolysis and Angioplasty in Myocardial Infarction-Phase 5 randomized trial. Circulation 83:1543-1556, 1991
  pubmed

• 18) TIMI Research Group:Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction:TIMI IIA results. JAMA 260:2849-2858, 1988

• 19) Carney, R. J., Murphy, G. A., Brandt, T. R. et al.:for the RAAMI Study Investigators:Randomized angiographic trial of recombinant tissue-type plasminogen activator (Alteplase) in myocardial infarction. J. Am. Coll. Cardiol. 20:17-23, 1992

• 20) Topol, E. J., George, B. S., Kereiakes, D. J. et al.:A randomized controlled trial of tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79:281-286, 1989
  pubmed

• 21) Grines, C. L., Nissen, S. E., Boorth, D. C. et al.:A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 84:540-549, 1991

• 22) Neuhause, K. L., von Essen, R., Tebbe, U. et al.:Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase:Results of the rt-PA-APSAC Patency Study(TAPS) . J. Am. Coll. Cardiol. 19:885-891, 1992

• 23) Hogg, K. J., Gemmill, J. D., Burns, J. M. A. et al.:Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction. Lancet 335:. 254-258, 1990
  pubmed

• 24) Relik-van Wely, L., Visser, R. F., van der Pol, J. et al.:Angiographically assessed coronary artery patency and reocculusion in patients with acute myocardial infarction treated with anistreplase:Results of the Anistreplase Reocclusion Multicenter Study (ARMS) . Am. J. Cardiol. 68:296-300, 1991

• 25) Neuhause, K. L., Feuerer, W., Jeep-Tebbe, S. et al.:Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. 14:1566-1569, 1989

• 26) Smalling, R. W., Schumacher, R., Morris, D. et al.:Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in acute myocardial infarction:Results of a multicenter randomized trial of two dosage regimens.J. Am. Coll. Cardiol. 15:915-921, 1990
  pubmed

• 27) Wall, T. C., Califf, R. M., George, B. S. et al.:for the TAMI-7 Study Group:Accelerated plasminogen activator dose regimens for coronary thrombolysis. J. Am. Coll. Cardiol. 19:482-489, 1992

• 28) ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3:A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339:753-770, 1992

• 29) Gruppo Italiano per Io Studio della Sopravvivenza nell, Infarcto Myocardico:GISSI-2:A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin amomg 12,490 patients with acute myocardial infarction. Lancet 336:65-71, 1990

• 30) Califf, R. M., Harrelson-Woodlief, L., Topol, E. J.:Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 82:1847-1853, 1990

• 31) Van de Werf, F.:Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1:1367-1369, 1989
  pubmed

• 32) Topol, E. J., Califf, R. M., Vandormael, M. et al. and the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group:A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 85:2090-2099, 1992

• 33) Brounwald, E.:Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 79:441-444, 1989

• 34) 0hman, E. M., Califf, R. M., Topol, E. J. et al.:Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781-791, 1990

• 35) Dellborg, M., Topol, E. J., Swedberg, K.:Dynamic QRS complex and ST segment vectrocardiographic monitoring and identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. Am. Heart J. 122:943-948, 1991

• 36) Kwon K. I., Freedman, B., Wilxos, I. et al.:The unstable ST segment early after thrombolysis for acute infarction and its usefulness as a marker of reccurent coronary occlusion. Am. J. Cardiol. 67:109-115, 1991

• 37) Topol, E. J., Califf, R. M., George, B. S. et al.:Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77:1100-1107, 1988
  pubmed

• 38) Vogt, A., von Essen, R., Tebbe, U. et al.:Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction:Retrospective analysis of four German multicenter studies.J. Am. Coll. Cardiol. 21:1391-1395, 1993
  pubmed

• 39) Bleich, S. D., Nichols, T. C., Schumacher, R. R. et al.:Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 66:1412-1417, 1990
  pubmed

• 40) de Bono, D. P., on behalf of the European Cooperative Study Group(ECSG-6):Effect of early intravenous heparin of coronary patency, infarct size, and bleeding complications after alteplase thrombolysis:Results of a randomised double blind European Cooperative Study Group(ECSG-6). Br. Heart J. 67:122-128, 1992

• 41) Hsia, J., Hamilton, W. P., Kleiman, N. et al.:A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N. Engl. Med. 323:1433-1437, 1990
  pubmed

• 42) Topol, E. J., Califf, R. M., George, B. S. et al.:A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasmonogen activator in acute myocardial infarction. N. Engl. J. Med. 317:581-588, 1987

• 43) Simoons, M. L., Betriu, A., Col, J. et al. for the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator(rt-PA) (ECSG-5):Thrombolysis with tissue plasminogen activator in acute myocardial infarction:No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1:197-202, 1988

• 44) Grines, C. L., Browne, K. F., Marco, J. et al.:A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N. Engl. Med. 328:673-679, 1993

• 45) Zijlstra, F., Boer, M. J., Hoorntje, J. C. A. et al.:A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N. Engl. J. Med. 328:680-684, 1993

P.195 掲載の参考文献

• 1) Lewis, H. D., Davis, J. W., Archibald, D. C. et al.:Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina:resulta of a Veterans Administation Cooperative Study. N. Engl. J. Med. 309:396-403, 1983

• 2) Cairns, J. A., Gent, M., Singer, J. et al.:Aspirin, sulfinpyrazone or both in unstable angina:results of a Canadian multicenter trial. JV. Engl. J. Med. 313:1369-1375, 1985
  pubmed

• 3) Theroux, P. et al.:Aspirin, heparin, or both to treat acute unstable angina. N. Engl. J. Med. 319:1105-1111, 1988

• 4) The RISC Group:Risk of myoardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336:827-830, 1990

• 5) Balsano, F., Rizzon, P., Violi, F. et al, for Studio della Ticlopidina nell'Angina Instabile Group.:Antiplatelet treatment with ticlopidine in unstable angina:acontrolled multicenter clinical trial. Circulation 82:17-26, 1990

• 6) Topol, E. J., Fuster, V., Harrington, R. A. et al.:Recombinant hirudin for unstable angina pectoris a multicenter, randomized angiographic trial. Circulation 89:1557-1566, 1994
  pubmed

• 7) The TIMI IIIB Investigators:Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction:results of the TIMI IIIB trial. Circulation 89:1545-1556, 1994

• 8) Cupples, L. A., Gagnon, D. R., Wong, N. D. et al.:Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction:The Framingham Study. Am. Heart J. 125:863-872, 1993
  pubmed

• 9) Yusuf, S., Peto, R., Lewis, J. et al.:Beta blockade during and after myocardial infarction:An overview of the randomized trials. Prog. Cardivasc. Dis. 27:335-371, 1985

• 10) Pfeffer, M. A., Braunwald, E., Moye, L. A. et al.:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N. Engl. J. Med. 327:669-677, 1992
  pubmed

• 11) Antiplatelet Trialists' Collaboration:Collaborative overview of randomized trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and storke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106, 1994

• 12) The Aspirin Myocardial Infarction Study Research Group:The aspirin myocardial infarction study:Final results. Circulation 62:V79-84, 1980

• 13) The Coronary Drug Project Research Group:Aspirin in coronary heart disease. J. Chrom. Dis. 29:625-642, 1976

• 14) The Persantine-Aspirin Reinfarction Study Research Group:Persantine and aspirin in coronary heart disease. Circulation 62:449-461, 1980

• 15) Klimt, C. R., Knatterud, G. L, Stamler, J. et al.:Persantine-Aspirin Reinfarction Study. Prat II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7:251-269, 1986

• 16) Elwood, P. C., Cochrane, A. L, Burr, M. L. et al:A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1:436-440, 1974
  pubmed

• 17) Elwood, P. C., Sweetnam, P. W.:Asirin and secondary mortality after myocardial infarction. Lancet 2:1313-1315, 1979

• 18) Breddin, K., Loew, D., Lechner, K. et al.:The German-Austrian Aspirin Trial:A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 62:V63-72, 1980

• 19) Vogel, G., Fischer, C., Huyke, R. et al.:Prevention of reinfarction withacetylsalicylic acid. In:Prophylaxis of venous, peripheral, cardiac and cerebral vascular diseases with acetylsalicylic acid. (eds:Breddin, H. K., Loew, D., Uberla, K. et al.), Stuttgart, Shattauer, 1981, p. 123-128

• 20) Fuster, V., Dyken, M. L., Vokonas, P. S. et al.:Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659-675, 1993
  pubmed

• 21) Janzon, L., Bergqvist, D., Bobberg, J. et al.:Prevention of myocardial infarction and stroke in patients with intermittent claudication;effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227:301-308, 1990
  pubmed

• 22) 石川欽司, 金政健, 浜純吉ほか:薬剤による心筋梗塞二次予防. 日本医事新報 3623:27-31, 1993

P.202 掲載の参考文献

• 1) Califf, R. M., Topol, E. J., Stack, R. S. et al.:Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction-phase 5 randomized trial. Circulation 83:1543-1556, 1991
  pubmed

• 2) Abbottsmith, C. W., Topol, E. J., George, B. S. et al.:Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J. Am. Coll. Cardiol. 16:770-778, 1990
  pubmed

• 3) 0hman, E. M., Califf, R. M., Topol, E. J. et al.:Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781-791, 1990

• 4) 0wen, J., Friedman, K. D., Grossman, B. A. et al.:Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72:616-620, 1988
  pubmed

• 5) Fitzgerald, D. J., Catella, F., Roy, L. et al.:Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77:142-150, 1988
  pubmed

• 6) Wall, T. C., Califf, R. M., George, B. S. et al.:For the TAMI-7 Study Group:Accelerated plasminogen activator dose regimens for coronary thrombolysis. J. Am. Coll. Cardiol. 19:482-489, 1992

• 7) Topol, E. J., Califf, R. M., George, B. S. et al.:Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77:1100-1107, 1988
  pubmed

• 8) The GUSTO Investigators.:An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329:673-682, 1993
  pubmed

• 9) Bleich, S. D., Nichols, T. C., Schumacher, R. R. et al.:Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 66:1412-1417, 1990
  pubmed

• 10) Hsia, J., Hamilton, W. P., Kleiman, N. et al.:A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N. Engl. J. Med. 323:1433-1437, 1990
  pubmed

• 11) Repodl, H. J., de Bono, D., Arnold, A. E. R. et al.:Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 85:928-934, 1992

• 12) de Bono, D. P., Simoons, M. L., Tijssen, J. et al.:Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis:results of a randomised double blind European Cooperative Study Group trial. Br. Heart J. 67:122-128, 1992

• 13) Coller, B. S., Peerschke, E. I., Scudder, L. E. et al.:A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.J. Clin. Invest. 72:325-338, 1983
  pubmed

• 14) Kleiman, N. S., Ohman, E. M., Califf, R. M. et al.:Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J. Am. Coll. Cardiol. 22:381-389, 1993
  pubmed

• 15) Topol, E. J., Ellis, S. G., Califf, R. M. et al.:Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J. Am. Coll. Cardiol. 14:877-884, 1989
  pubmed

• 16) Weitz, J. I., Hudoba, M. et al.:Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86:389-391, 1990

• 17) Hanson, S. R. et al.:Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-propyl-L-arginyl chloromethylketone. Proc. Natl. Acad. Sci. USA 85:3184-3188, 1988

• 18) Talbot, M. D. et al:Recombinant desulphatohirudin (CGP39393), anticoagulant and antithrombotic properties in vivo. Thromb. Haemost. 61:77-80, 1989

• 19) Okamoto, S., Hijikata, A. et al:Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem. Biophys. Res. Commun. 101:440-446, 1981
  pubmed

• 20) 水野杏一, 荒川宏, 渋谷利雄ほか:急性心筋梗塞に対する再灌流療法の選択と急性冠閉塞予防法. Jpn. Circ. J. 56 (Suppl V):238-242, 1992

• 21) Neuhaus, K. L., Essen, R. V., Tebbe, U. et al.:Hirudin and thrombolysis with front-loaded alteplase in acute myocardial infarction:results of a pilot study. J. Am. Coll. Cardiol. 21:418A, 1993

• 22) Lidon, R. M., Theroux, P., Lesperance, J. et al:A pilot, early angiographic patency study using adirect thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circula tion 89:1567-1572, 1994

• 23) Theroux, P., Perez-Villa, F., Waters, D. et al.:Randomized double-blind comparison of two doses of hilulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132-2139, 1995
  pubmed

• 24) De Feyter, P. J., De Jaegere, P. P. T., Serruys, P. W.:Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am. Heart J. 127:643-651, 1994

• 25) Topol, E. J.:Emerging strategies for failed percutaneous transluminal coronary angioplasty. Am. J. Ca rdiol. 63:249-250, 1989

• 26) Noda-Heiny, H., Fujii, S., Sobel, B. E.:Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ. Res. 72:36-43, 1993
  pubmed

• 27) Gruentzig, A. R., Senning, A., Siegenthaler, W. E.:Nonoperative dilation of coronary artery stenosis:Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301:61-71, 1979

• 28) DeFeyter, P. J., VanDen Brand, M., Jaarman, G. et al.:Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, and follow-up. Circulation 83:927-936, 1991

• 29) Lincoff, A. M., Popma, J. J., Ellis, S. G. et al.:Abrupt vessel closure complicating coronary angioplasty:Clinical, angiographic and therapeutic profile. J. Am. Coll. Cardiol. 19:926-935, 1992

• 30) McGarry, T. F. Jr., Gottlieb, R. S., Morganroth, J. et al.:The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am. Heart J. 123:1445-1451, 1992
  pubmed

• 31) Lukas, M. A., Deutsch, E., Iaskey, W. K.:Beneficial effect of heparin therapy on PTCA outcome in unstable angina. J. Am. Coll. Cardiol. 11 (Suppl):132A, 1988

• 32) Barnathan, E. S., Schwartz, J. S., Taylor, L. et al.:Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76:125-134, 1987
  pubmed

• 33) The EPIC Investigators.:Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330:956-961, 1994
  pubmed

• 34) Anderson, H. V., Kirkeeide, R. L, Krishnaswami, A. et al.:Cyclic flow variations after coronary angioplasty in humans:Clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J. Am. Coll. Cardiol. 23:1031-1037, 1994
  pubmed

• 35) Konstantopoulos, K., Kamat, S. G., Schafer, A. I. et al.:Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circzalation 91:1427-1431, 1995
  pubmed

• 36) Tcheng, J. E., Harrington, R. A., Kottke-Marchant, K. et al. (IMPACT Investigators):Multicentor, randomized, double-blind, placebo-controlled trial of the platelet integrin glyco-protein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 91:2151-2157, 1995

• 37) van den Bos, A. A., Deckers, J. W., Heyndrickx, G. R. et al.:Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circzalation 88 (part I):2058-2066, 1993

• 38) Topol, E. J., Bonan, R., Jewitt, D. et al.:Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622-1629, 1993
  pubmed

• 39) 鈴木俊示, 坂本丞, 足立和正ほか:急性冠動脈閉塞における argatroban 投与の効果. Coronary 11 (Suppl):70-74, 1994

• 40) Haskel, E. J., Adams, S. P., Feigen, L. P. et al.:Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IHa receptors. Circulation 80:1775-1782, 1989

• 41) Declerk, F. B., Khonneux, L, Van Gorp, L. et al.:S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin H, receptor blockade (BM 13, 177):Enhanced anti-platelet effect. Thromb. Haemost. 56:236, 1986

• 42) Golino, P., Ashton, J. H., McNatt, J. et al.:Simultaneous administration of thromboxane A2-and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombolysis. Circulation 79:911-919, 1989
  pubmed

• 43) Vaughan, D. E., Plavin, S. R., Schafer, A. L et al.:Prostaglandin E,accelerates thrombolysis by tissue plasminogen activator. Blood 73:1213-1217, 1989

• 44) Shebuski, R. J., Berry, D. E., Bennett, D. B. et al.:Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb, Haemost. 61:183-188, 1989
  pubmed

• 45) Huang, T-F., Holt, J. C., Lukasiewicz, H. et al:Trigramin:Alow molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed in glycoprotein IIb/IIIa complex. J. Biol. Chem. 262:16157-16163, 1987

• 46) Gan, Z-R., Gould, R. J., Jacobs, J. W. et al.:Echistatin:A potent platelet aggregation inhibitor from the venom of the viper. Echis carinatus. J. Biol. Chem. 263:19827-19832, 1988
  pubmed

• 47) Shebuski, R. J., Ramjit, D. R., Bencen, G. H. et al.:Characterization and platelet inhibitory activity of bitistatin, a potent RGD-containing peptide from the venom of the viper Bitis arietans. J. Biol. Chem. 264:21550-21556, 1989

• 48) Mickelson, J. K., Simpson, P. J., Cronin, M. et al.:Antiplatelet antibody [7E3 F (ab'2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 81:617-627, 1990

• 49) Markland, F. S., Friedrichs, G. S., Pewitt, S. R. et al.:Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 90:2448-2456, 1994
  pubmed

• 50) Roux, S. P., Tschopp, T. B., Kuhn, H. et al.:Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J. Pharmacol. Exp. Ther. 264:501-508, 1993

• 51) Shebuski, R. J., Stabilito, I. J., Sitko, G. R. et al.:Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 82:169-177, 1990

• 52) Yasuda, T., Gold, H. K. et al.:Kistrin, a polypeptide platelet GP IIb/IIIa receptor antagonist, enhances and sustains coronary anterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 83:1038-1047, 1991

• 53) Biemond, B. J., Levi, M., Coronel, R. et al.:Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombolysis. Effects of plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 91:1175-1181, 1995
  pubmed

• 54) Yasuda, T., Gold, H. K., Yaoita, H. et al.:Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J. Am. Coll. Cardiol. 16:714-722, 1990

• 55) Prager, N. A., Torr-Brown, S. R., Sobel, B. E. et al.:Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J. Am. Coll. Cardiol. 22:296-301, 1993
  pubmed

• 56) Jang, I. K., Gold, H. K., Leinbach, R. C. et al.:In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ. Res. 67:1552-1561, 1990
  pubmed

• 57) Bates, E. R., McGillem, M. J., Mickelson, J. K. et al.:Amonoclonal antibody against the platelet glycoprotein Ilb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 84:2463-2469, 1991

• 58) Turner, N. A., Moake, J. L, Kamat, S. G. et al.:Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 91:1354-1362, 1995
  pubmed

• 59) Meyer, B. J., Fernandez Ortiz, A., Mailhac, A. et al.:Local delivary of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 90:2474-2480, 1994-

• 60) Shi, Y., Nardone, D., Hernandez-Martinez, A. et al.:Fibrinolytic activity after vessel wall injury. J. Am. Coll. Cardiol. 19:441-443, 1992

P.211 掲載の参考文献

• 1) Petersen, P.:Thromboembolic complications of atrial fibrillation and their prevention. A review. Am. J. Cardiol. 65:21C-28C, 1990

• 2) Chesebro, J. H., Fuster, V., Halperin, J. L.:Atrial fibrillation-risk marker for stroke. N. Engl. J. Med. 323:1556-1558, 1990
  pubmed

• 3) Cerebral Embolism Task Force:Cardiogenic brain embolism. Arch. Neurol. 43:71-84, 1986
  pubmed

• 4) Cerebral Embolism Task Force:Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch. Neurol. 46:727-743, 1989
  pubmed

• 5) Caims, J. A., Connolly, S. J.:Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 84:469-481, 1991

• 6) Albers, G. W., Atwood, J. E., Hirsh, J. et al.:Stroke prevention in nonvalvular atrial fibrillation. Ann. Intern. Med. 115:727-736, 1991
  pubmed

• 7) Hart, R. G.:Cardiogenic embolism to the brain. Lancet 339:589-594, 1992

• 8) Petersen, P., Boysen, G., Godtfredsen, J. et al.:Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet i:175-178, 1989
  pubmed

• 9) The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators:The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. JV. Engl. J. Med. 323:1505-1511, 1990

• 10) Stroke Prevention in Atrial Fibrillation Investigators:Stroke prevention in atrial fibrillation study. Final results. Circulation 84:527-539, 1991

• 11) Connolly, S. J., Laupacis, A., Gent, M. et al.:Canadian atrial fibrillation anticoagulation (CAFA) study. J. Am. Coll. Cardiol. 18:349-355, 1991
  pubmed

• 12) Ezekowitz, M. D., Bridgers, S. L., James, K. E. et al.:Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N. Engl. J. Med. 327:1406-1412, 1992
  pubmed

• 13) Halperin, J. L, Hart, R. G.:Atrial fibrillation and stroke:new ideas, persisting dilemmas. Stroke 19:937-941, 1988

• 14) 堀正二, 是恒之宏:心房細動患者の塞栓症に対する抗血小板療法の多施設長期臨床計画試験と予備調査. Jpn. Circ. J. 58 (Suppl. IV):1313-1315, 1995

• 15) Petersen, P., Godtfredsen, J.:Embolic complications in paroxysmal atrial fibrillation. Stroke 17:622-626, 1986
  pubmed

• 16) EAFT (European Atrial Fibrillation Trial) Study Group:Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342:1255-1262, 1993
  pubmed

• 17) Lown, B.:Electrical reversion of cardiac arrhythmia. Br. Heart J. 29:469-489, 1967
  pubmed

• 18) Selzer, A., Kelly, J., Johnson, R. B. et al.:Immediate and long term results of electrical cardioversion of arrhythmia. Prog. Cardiovasc. Dis. 9:90-104, 1966

• 19) Resnekov, L., McDonald, L.:Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroversion. Br. Heart J. 29:9236, 1967

• 20) Aberg, H., Cullhed, I.:Direct current countershock complications. Acta. Med. Scand. 183:415-421, 1968
  pubmed

• 21) Bjerkelund, C. J., Orning, 0. M.:The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am. J. Cardiol. 23:208-216, 1969

• 22) Henry, W. L, Morganroth, J., Pearlman, A. S. et al.:Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 53:273-279, 1976
  pubmed

• 23) Laupacis, A., Albers, G., Dunn, M. et al.:Antithrombotic therapy in atrial fibrillation. Third ACCP Conference on Antithrombotic Therapy. Chest 102(Suppl.):426S-433S, 1992

• 24) Grimm, R. A. ., Stewart, W. J., Black, I. W. et al.:Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation?J. Am. Coll. Cardiol. 23:533-541, 1994
  pubmed

P.231 掲載の参考文献

• 1) 青崎正彦:人工弁置換と血栓塞栓症. 血液と脈管 16:117-139, 1985

• 2) Aosaki, M., Koyanagi, H., Terada, K. et al.:Present status of thromboembolic complications in patients with prosthetic heart valves. Jpn. Circ. J. 50:884-887, 1986
  pubmed

• 3) 青崎正彦, 上塚芳郎, 細田瑳一ほか:人工弁と血栓症. 内科 63:670-678, 1989

• 4) Chesebro, J. H., Fuster, V.:Valvular heart disease and prosthetic heart valves. 1n:Thrombosis in Cardiovascular Disorders (eds:Fuster, V., Verstraete, M.), W. B. Saunders, Philadelphia, 1992, p. 191-214

• 5) Israel, D. H., Sharma, S. K., Fuster, V.:Antithrombotic therapy in prosthetic heart valve replacement. Am. Heart J. 127:400-411, 1994
  pubmed

• 6) Stein, P. D., Alpert, J. S., Copeland, J. et al.:Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 102 (Suppl):445S-455S, 1992

• 7) Cannegieter, S. C., Rosendaal, F. R., Briet, E.:Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635-641, 1994
  pubmed

• 8) 上塚芳郎, 細田瑳一, 青崎正彦ほか:経口抗凝血薬療法におけるトロンボテスト (%) とプロトロンビン時間 (INR) の臨床的意義について. 血栓止血誌 3:123-130, 1992

• 9) Nakano, K., Koyanagi, H., Hashimoto, A. et al.:Twelve years:experience with the St. Jude Medical valve prosthesis. Ann. Thorac. Surg. 57:697-703, 1994
  pubmed

• 10) 風間睦美, 安部英:経口抗凝固療法ガイドライン. British Committee for Standardization in Haemostasis and Thrombosis Task Forceの報告 (1984. 5) に基づく. 血液と脈管 16:431-439, 1985

• 11) 青崎正彦, 細田瑳一:投与の実際. ワーファリン (前川正, 細田瑳一, 斉藤英彦監修), メディカル・ジャーナル社, 東京, 1990, p.43-73

• 12) Poller, L.:Therapeutic ranges for oral anticoagulation in different thromboembolic disorders. Ann. Hematol. 64:52-59, 1992
  pubmed

• 13) Butchart, E. G., Lewis, P. A., Bethel, J. A. et al.:Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 84 (Suppl. III):HI-61-III-69, 1991

• 14) Wilson, D. B., Dunn, M. I., Hassanein, K.:Low. intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 100:1553-1557, 1991
  pubmed

• 15) Horstkotte, D., Schulte, H. D., Bircks, W. et al.:Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J. Thorac. Cardiovasc. Surg. 107:1136-1145, 1994
  pubmed

• 16) Hirsh, J., Dalen, J. E., Deykin, D. et al.:Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 102 (Suppl):312 S-326S, 1992

• 17) 青崎正彦:人工弁置換術後の抗血栓療法:ワーファリン単独か抗血小板薬併用か? (b)ワーファリン 抗血 小板薬の併用を優先する立場から. 血栓と循環 3:160-165, 1995

• 18) Altman, R., Rouvier, J., Gurfinkel, E. et al.:Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J. Thorac. Cardiovasc. Surg. 101:427-431, 1991
  pubmed

• 19) British Society for Haematology, British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force:Guidelines on oral anticoagulation:second edition. J. Clin. Pathol. 43:177-183, 1990
  pubmed

• 20) 青崎正彦:経口抗凝血薬療法の臨床. 食事の影響, 薬物相互作用を中心に. 呼と循 39. 779-788, 1991

• 21) Levine, M. N., Hirsh, J., Landefeld, S. et al.:Hemorrhagic complications of anticoagulant treatment. Chest 102 (Suppl):352S-363S, 1992

• 22) Czer, L. S. C., Chaux, A., Matloff, J. M. et al.:Ten-year experience with the St. Jude Medical valve for primary valve replacement. J. Thorac. Cardiovasc. Surg. 100:44-55, 1990

• 23) Roudaut, R., Labbe, T., Lorient-Roudaut, M-F. et al.:Mechanical cardiac valve thrombosis. Is fibrinolysis justified?Circulation 86 (Suppl. II):II-8-II-15, 1992

• 24) Kurzrok, S., Singh, A. K., Most, A. S. et al.:Thrombolytic therapy for prosthetic cardiac valve thrombosis. J. Am. Coll. Cardiol. 9:592-598, 1987
  pubmed

• 25) 高山鉄郎:人工弁置換術後早期の血栓形成要因とその抑制-抗血小板薬併用療法について-. 日胸外会誌 33:14-24, 1985

• 26) 青崎正彦, 大木勝義, 岩出和徳:ワーファリン投与の実際. 日常診療と血液 3:24-34, 1993

• 27) Hirsh, J., Ginsberg, J. S., Marder, V. J.:Anticoagulant therapy with coumarin agents. In:Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd ed, (eds:Colman, R. W., Hirsh, J., Marder, V. J. et al.), J. B. Lippincott, Philadelphia, 1994, p. 1567-1583

• 28) Baudet, E. M., Oca, C. C., Roques, X. F. et al.:A 5-year experience with the St. Jude Medical cardiac valve prosthesis. Eearly and late results of 737 valve replacements in 671 patients. J. Thorac. Cardiovasc. Surg. 90:137-144, 1985

• 29) Hartz, R. S., LoCicero, J. HI., Kucich, V. et al.:Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J. Thorac. Cardiovasc. Surg. 92:684-690, 1986

• 30) Ribeiro, P. A., Zaibag, M. A., Idris, M. et al.:Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease. J. , Thorac. Cardiovasc. Surg. 91:92-98, 1986

• 31) DiSesa, V. J., Collins, J. J. Jr., Cohn, L. H.:Hematological complications with the St. Jude valve and reduced-dose coumadin. Ann. Thorac. Surg. 48:280-283, 1989
  pubmed

• 32) Vogt, S., Hoffmann, A., Roth, J. et al.:Heart valve replacement with the Bjork-Shiley and St. Jude Medical prostheses:arandomized comparison in 178 patients. Eur. Heart J. 11:583-591, 1990

• 33) Horstkotte, D., Korfer, R., Seipel, L. et al.:Late complications in patients with Bjork-Shiley and St. Jude Medical heart valve replacement. Circulation 68 (Suppl. II):II-175-II-184, 1983

• 34) Kopf, G. S., Hammond, G. L., Geha, A. S. et al.:Long-term performance of the St. Jude Medical valve:low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 76 (Suppl. III):III-132-III-136, 1987

• 35) Eberlein, U., von der Emde, J., Rein, J. et al.:Thromboembolic and bleeding complications after mitral valve replacement. Eur. J. Cardiothorac. Surg. 4:605-612, 1990
  pubmed

• 36) 青崎正彦, 岩出和徳, 大木勝義:凝固・線溶系. Chronic Disease 5:345-359, 1994

• 37) Marongiu, F., Sorano, G. G., Mameli, G, et al.:Thrombin activity and oral anticoagulant therapy:afurther evaluation. Haemostasis 20:63-64, 1990

• 38) 内山俊正, 金沢紀雄, 佐々木豊志ほか:経口抗凝血薬療法による血管内トロンビン生成の制御に関する研究-トロンビン・アンチトロンビンIII複合体 (TAT) による検討-. 血栓止血誌 3:231-237, 1992

• 39) Takahashi, H., Wada, K., Satoh, N. et al.:Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1+2. Blood Coagul. Fibrinolysis 4:435-439, 1993
  pubmed

• 40) Iwade, K., Aosaki, M., Ohki, K. et al.:Suppression of coagulation by oral anticoagulants in patients with mechanical heart valve prostheses. Thromb. Haemost. 69:677, 1993

• 41) Bernardo, A., Halhuber, C., Horstkotte, D.:Home, prothrombin estimation. In:Thrombosis, Embolism and Bleeding (eds:Butchart, E. G., Bodnar, E.), ICR Publishers, London, 1992, p. 325-330

• 42) Furie, B., Diuguid, C. F., Jacobs, M. et al.:Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 75:344-349, 1990
  pubmed

• 43) Kornberg, A., Francis, C. W., Pellegrini, V. D. Jr. et al.:Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 88:454-460, 1993
  pubmed

• 44) Loeliger, E. A., Broekmans, A. W.:Optimal therapeutic anticoagulation. Haemostasis 15.:283-292, 1985
  pubmed

• 45) Moggio, R. A., Hammond, G. L., Stansel, H. C. Jr. et al.:Incidence of emboli with cloth-covered Starr-Edwards valve without anticoagulation and with varing forms of anticoagulation. Analysis of 183 patients followed for 3?years. J. Thorac. Cardiovasc. Surg. 75:296-299, 1978

• 46) Sutton, M. G. St. J., Miller, G. A. H., Oldershaw, P. J. et al.:Anticoagulants and the Bjork-Shiley prosthesis. Experience of 390 patients. Br. Heart J. 40:558-562, 1978

• 47) Thevenet, A.:Lillehei-Kaster prosthesis in the aortic position with and without anticoagulants. J. Cardiovasc. Surg. 21:669-674, 1980
  pubmed

• 48) Groupe de recherche P. A. C. T. E.:Prevention des accidents thrombo-emboliques systemiques chez les porteurs de prostheses valvulaires artificielles:essai cooperatif controle du dipyridamole. Caeur 9:915-969, 1978

• 49) Sullivan, J. M., Harken, D. E., Gorlin, R.:Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circualtion 39 & 40 (Suppl):1-149-1-153, 1969

• 50) Chesebro, J. H., Fuster, V., Elveback, L. R. et al.:Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement:danger of aspirin compared with dipyridamole. Am. J. Cardiol. 51:1537-1541, 1983
  pubmed

• 51) Rajah, S. M., Sreeharan, N., Joseph, A. et al.:A prospective trial of dipyridamole and warfarin in heart valve patients. Acta Therapeutica 6:54, 1980

• 52) 笠原卓:人工弁置換術後における dipyridamole 投与の臨床的効果に関する研究 (特に血液凝固能におよぼす影響について) . 日胸外会誌 25:1007-1021, 1977

• 53) Turpie, A. G. G., Gent, M., Laupacis, A. et al.:Acomparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N. Engl. J. Med. 329:524-529, 1993

• 54) Skudicky, D., Essop, M. R., Wisenbaugh, T. et al:Frequency of prosthetic valve-related complications with very low level warfarin anticoagulation combined with dipyridamole after valve replacement using St. Jude Medical prostheses. Am. J. Cardiol. 74:1137-1141, 1994
  pubmed

• 55) Altman, R., Boullon, F., Rouvier, J. et al.:Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J. Thorac. Cardiovasc. Surg. 72:127-129, 1976
  pubmed

• 56) Dale, J., Myhre, E., Storstein, O. et al.:Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am. Heart J. 94:101-111, 1977
  pubmed

• 57) Dale, J., Myhre, E., Loew, D.:Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am. Heart J. 99:746-752, 1980
  pubmed

• 58) Sullivan, J. M., Harken, D. E., Gorlin, R.:Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N. Engl J. Med. 284:1391-1394, 1971
  pubmed

• 59) Turpie, A. G. G., Gunstensen, J., Hirsh, J. et al.:Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet i:1242-1245, 1988

• 60) Saour, J. N., Sieck, J. O., Mamo, L. A. R. et al.:Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N. Engl. J. Med. 322:428-432, 1990

• 61) Mok, C. K., Boey, J., Wang, R. et al.:Warfarin versus dipyridamole. aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism:a prospective randomized clinical trial. Circulation 72:1059-1063, 1985
  pubmed

• 62) Hayashi, J., Nakazawa, S., Oguma, F. et al.:Combined warfarin and antiplatelet therapy after St. Jude Medical valve replacement for mitral valve disease. J. Am. Coll. Cardiol. 23:672-677, 1994

• 63) 青崎正彦:抗凝血薬 抗血小板薬を服用中の患者に外科的処置をするには. JIM 3:419-421, 1993

• 64) 福井尚見:置換弁心内膜炎における血栓塞栓症と抗凝血薬療法. 東女医大誌 57:1714-1725, 1987

• 65) 青崎正彦, 木全心一:心臓. A. 心疾患. ワーファリン (前川正, 細田瑳一, 斉藤英彦 監修), メディカル・ジャーナル社, 東京, 1990, p.105-135

• 66) Sherman, D. G., Dyken, M. L., Fisher, M. et al.:Antithrombotic therapy for cerebrovascular disorders. Chest 95 (Suppl):140S-155S, 1989

• 67) Hall, J. G., Pauli, R. M., Wilson, K. M.:Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med. 68:122-140, 1980
  pubmed

• 68) 上塚芳郎, 東館紀子, 青崎正彦ほか:人工弁置換後妊娠・分娩例の21名, 24妊娠の予後に関する研究. J. Cardiology 20:929-935, 1990

• 69) Born, D., Martinez, E. E., Almeida, P. A. M. et al.:Pregnancy in patients with prosthetic heart valves:the effects of anticoagulation on mother, fetus, and neonate. Am. Heart J. 124:413-417, 1992

• 70) Ginsberg, J. S., Hirsh, J.:Use of antithrombotic agents during pregnancy. Chest 102 (Suppl):385S-390S, 1992

• 71) 小柳仁, 新岡俊治, 沢谷修ほか:人工弁と社会復帰. 人工臓器 14:527-530, 1985

• 72) Sbarouni, E., Oakley, C. M.:Outcome of pregnancy in women with valve prostheses. Br. Heart J. 71:196-201, 1994
  pubmed

• 73) Salazar, E, Zajarias, A., Gutierrez, N. et al.:The problem of cardiac valve prostheses, anticoagulants, and pregnancy. Circulation 70 (Suppl. 1):1-169-1-177, 1984

• 74) Lee, P. K., Wang, R. Y. C., Chow, J. S. F. et al.:Combined use of warfarin and adjusted subcutaneous heparin during pregnancy in patients with an aritficial heart valve. J. Am. Coll. Cardiol. 8:221-224, 1986

• 75) Meyers, K. E., Nakamura, J. M.:Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Cardiol. 65:1410, 1990

• 76) Stirling, Y., Woolf, L., North, W. R. S. et al.:Haemostasis in normal pregnancy. Thromb. Haemost. 52:176-182, 1984

P.243 掲載の参考文献

• 1) Wilson, J. E. HI:Pulmonary embolism:diagnosis and treatment. Clin. Notes. Respir. Dis. 19:3-7, 1981

• 2) Walsh, P. N., Stengle, J. N., Sherry, S.:Urokinase pulmonary embolism trial. A national cooperative study. Circulation 47:1-108, 1973

• 3) Urokinase Pulmonary Embolism Trial Group:Urokinase pulmonary embolism trial:phase I result. JAMA 214:2163-3172, 1970

• 4) William, R. B., Allen, G. M.:Guidelines for the use of thrombolytic agent. N. Engl. J. Med. 301:1267-1270, 1979

• 5) The UKEP study research group:The UKEP study:Multicenter clinical trial on two local regimens of urokinase in massive pulmonary embolism. Euro. R. J. 8:2-10, 1987

• 6) 吉良枝郎, 三重野龍彦:わが国における血栓塞栓性肺血管疾患の現状. 脈管学 29:585-589, 1989

• 7) Goldhaber, S. Z., Heit, J., Shrma, G. V. R. K. et al.:Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2:293-298, 1988

• 8) Dalen, J. E., Banas, J. S. Jr., Brooks, H. L. et al.:Resolution rate of acute pulmonary embolism in man. N. Engl. J. Med. 280:1194-1199, 1969

• 9) Steven, D. S., Edward, J. C.:Pulmonary diseases. manual of medical therapeutics. 26th edition. 1986, p.203-211

• 10) 長田博:肺血栓塞栓症の内科的治療. 日胸疾会誌 26:478-485, 1988

• 11) 田辺信宏, 栗山喬之:肺血栓塞栓症の治療上の進歩. 現代医療 25:90-95, 1993

• 12) Francis, R. B. Jr., McGehee, W. G.:Defibrination during warfarin therapy in a man with protein C deficiency. Thromb. Haemost. 53:249-251, 1985

• 13) Meyer, G., Sors, H., Charbonnier, B. et al.:Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism:AEuropean Multi Center Double-Blind Trial. J. Am. Coll. Cardiol. 19:239-245, 1992

• 14) 長田博, 川上義和:肺血栓 塞栓の治療. 呼と循 37:961-965, 1989

• 15) 国枝武義, 大久保俊平, 吉岡公夫ほか:肺血管塞栓症:血栓溶解療法の効果を中心に. 脈管学 31:291-295, 1991

• 16) Meneveau, N., Bassand, J. P., Schieles, F. et al.:Safety of thrombolytic therapy in eldery patients with massive pulmonary embolism;Acomparison with nonelderly patient. J. Am. Coll. Cardiol. 22:1075-1079, 1993

• 17) Matsuo, 0. Rijken, D. C., Collen, D.:Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291:590-591, 1981

• 18) Levine, M., Hersh, J., Weitz, J. et al.:Arandomised Trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 98:1473-14779, 1990

• 19) 古寺研一:経皮的下大静脈フィルター挿入術, Gunther vena caval filterの使用経験. 日本医放会誌 49:168-171, 1989

• 20) Gunther, R. W., Schild, H., Hollman, J. P. et al.:First Clinical results with a new caval filter. Cardiovasc. In terven t. Radiol. 10:104-108, 1987

• 21) Ansari, A.:Acute and chronic pulmonary thromboembolism:Cullent perspectives. Part I:Glossary of terms, historic evolution and prevalence. Clin. Cardiol. 9:398-402, 1986
  pubmed

• 22) Moser, K. M., Auger, W. R., Fedullo P. F. et al.:Chronic thromboembolic pulmonary hypertension;Clinical picture and surgical treatment. Eza r. Respir. J. 5:334-342, 1992

• 23) Goldhaber, S. Z.:Pulmonary embolism and deep venous thrombosis. WB Saunders, 1985, p. 121

• 24) 栗山喬之:慢性肺血栓塞栓症. 日内会誌 82:1560-1565, 1993

• 25) Sasahara, A. A., Hyers, T. M., Cole, C. M. et al.:The urokinase pulmonary embolism trial:A national cooperative study. Circulation 47 (Suppl. II):1-108, 1973

• 26) 長田博, 川上義和:肺血栓塞栓症に対する血栓溶解療法. Ccurrent Therapy 9:84-88, 1991

• 27) 笹川康夫, 服部晃, 和泉徹ほか:肺血栓塞栓症のウロキナーゼによる血栓溶解療法-18例の集計成績. 呼と循 37:83-86, 1989

• 28) Goldhaber, S. Z., Harie, W. D., Feldstein, M. L. et al.:Alteplase versus heparin in acute pulmonary embolism:randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 341:507-511, 1993

• 29) 瀧島. 任, 白土邦男, 北村論ほか:肺血栓塞栓症に対する遺伝子組換えヒトt-PA (TD-2061) の静脈内単回 投与法による臨床研究. 診断と治療 81:154-173, 1993

• 30) 長谷川直樹, 市瀬裕一, 岡田泰昌ほか:組織型プラスミノーゲンアクチベータによる血栓溶解療法が奏功 した急性肺血栓塞栓症の一例. 日胸 50:1004-1009, 1991

• 31) Mitchell, J. P., Trulock, E. P., Missouri, S. T. L.:Tissue-plasminogen activator for pulmonary embolism resulting in shock:Two case reports and discussion of the literature. Am. J. Med. 90:255-260, 1991

P.266 掲載の参考文献

• 1) Whisnant, J. P., Basford, J. R., Bernstein, B. F. et al.:Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21:637-676, 1990

• 2) 内山真一郎:脳血栓 脳塞栓 TIA. 臨床血栓止血学 (櫻川信雄, 池田康夫編), 医歯薬出版, 東京, 1994, p.342-347

• 3) 内山真一郎:脳血栓症およびTIA. 血栓症治療ハンドブック (改訂版) (池田康夫編), メディカルレビュー社, 東京, 1995, p.31-44

• 4) 内山真一郎:心原性脳塞栓症. 血栓症治療ハンドブック (改訂版) (池田康夫編), メディカルレビュー社, 東京, 1995, p.45-54

• 5) 内山真一郎:脳血管障害の抗血栓療法. 特集:脳血管障害へのアプローチ. 内科72:511-520, 1993

• 6) 内山真一郎:抗血小板薬. 新時代を迎えた脳血栓症の治療 (藤島正敏, 山口武典編), メディカルトリビューン, 東京, 1993, p.91-106

• 7) 内山真一郎:脳梗塞の抗凝固療法の実際. CT MRI時代の脳卒中学-新しい診断 治療体系-上巻. 日本臨床 (増刊) 51:458-462, 1993

• 8) 田崎義昭, 小林祥泰, 東儀英夫ほか:脳血栓症急性期に対する抗トロンビン薬MD-805の臨床的有用性. 医薬のあゆみ 161:887-907, 1992

• 9) Kay, R., Wong, K. S., Yu, Y. L. et al.:Low-molecular-weight heparin for the treatment of acute ischemic stroke. N. Engl. J. Med. 333:1588-1593, 1995
  pubmed

• 10) Astrup, S., Siesjo, G. K., Symon, L. et al.:Threshold in cerebral ischemia-The ischemic penumbra. Stroke 12:723-725, 1981

• 11) Braunwald, E., Kloner, R.:Myocardial reperfusion:A double-edged sword?J. Clin. Invest. 76:1713-1719, 1985

• 12) Ames, A., Wright, R. L, Kowada, M. et al.:Cerebral ischemia II. The no-reflow phenomenon. Am. J. Pathol. 52:437-453, 1968
  pubmed

• 13) Levy, D. E., Van Uitert, R. L, Pike, C. L. et al.:Delayed postischemic hypoperfusion:A potentially damaging consequence of stroke. Neurology 29:1245-1252, 1979
  pubmed

• 14) 内山真一郎, 望月昌子, 鄭秀明ほか:虚血性脳卒中におけるindium-111 tropoloneによる抗血栓療法の 評価. 神経内科治療 8:57-62, 1991

• 15) Harlan, J. M., Harker, L. A.:Hemostasis, thrombosis and thromboembolic disorders. The role of arachidonic acid metabolites in platelet-vessel wall interaction. Med. Clin. North,Am. 65:855-879, 1981
  pubmed

• 16) Dempsy, R. J., Roy, M. W., Meyer, K.:Polyamine and prostaglandin markers in focal cerebral ischemia. Neurosurgery 17:635-640, 1985

• 17) 佐渡島省三, 石束隆男, 藤井健一郎ほか:実験的脳虚血に及ぼすトロンボキサン合成酵素阻害剤 (OKY-046) の効果-脳血流と脳組織代謝. 脳卒中 11:373-380, 1989

• 18) 森悦朗:血栓溶解薬. 新時代を迎えた脳血栓症の治療 (藤島正敏,山口武典編), メディカルトリビューン, 東京, 1993, p.83-91

• 19) Millikan, C., Futrell, N.:The fallacy of the lacune hypothesis. Stroke 21:1251-1257, 1990
  pubmed

• 20) Tei, H., Uchiyama, S., Maruyama, S.:Capsular infarcts:Location, size and etiology of pure motor hemiparesis, sensory motor stroke and ataxic hemiparesis. Acta Neurol. Scand. 88:269-273, 1993

• 21) 峰松一夫:脳梗塞病型分類とその鑑別. 新時代を迎えた脳血栓症の治療 (藤島正敏, 山口武典編), メディカルトリビューン, 東京, 1993, p. 23-33

• 22) Cerebral Embolism Task Force:Cardiogenic brain embolism. Arch. Neurol. 43:71-84, 1986
  pubmed

• 23) 内山真一郎:心原性脳塞栓症の再発予防と予後. CT MRI時代の脳卒中学-新しい診断 治療体系-上巻. 日本臨床 (増刊) 51:620-627, 1993

• 24) 岡田靖:心原性脳梗塞:急性期の治療-血栓溶解療法-. CT MRI時代の脳卒中学-新しい診断 治療体系-上巻. 日本臨床 (増刊) 51:615-619, 1993

• 25) Striefler, J. Y., Furlan, A. J., Barnett, H. J. M.:Cardiogenic brain embolism:incidence, varieties, treatment. Stroke:Pathophysiology, Diagnosis and Management. (eds:Barnett, H. J. M., Mohr, J. P., Stein, B. M. et al.), Churchill Livingston, New York, 1992, p.967-994

• 26) 内山真一郎:抗血小板 抗凝固療法の開始時期と投与期間. 特集:Part2 慢性期虚血性脳血管障害への対策. Mebio 3:76-81, 1995

• 27) Brott, T.:Thrombolytic and defibrinogenating agents for ischemic and hemorrhagic stroke. Stroke:Pathophysiology, Diagnosis and Management. (eds:Barnett, H. J. M., Mohr, J. P., Stein, B. M. et al.:Churchill Livingston, New York, 1992, p.953-965

• 28) Antiplatelet Trialists:Collaboration:Collaborative overview of randamised trials of antiplatelet therapy-1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106, 1994

• 29) 内山真一郎:虚血性脳血管障害とプロスタグランジン. 脳血管障害とプロスタグランジン. 現代医療 25:1783-1790, 1993

• 30) Uchiyama, S., Sone, R., Nagayama, T. et al.:Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 20:1643-1647, 1989
  pubmed

• 31) Dyken, M. L, Barnett, H. J. M., Easton, D. et al.:Low-dose aspirin and stroke:it ain't necessarily so. Stroke 23:1395-1399, 1992

• 32) Hass, W. K., Easton, J. D., Adams, H. P. et al. for the Ticlopidine-Aspirin Stroke Study Group:A randamized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N. Engl. J. Med. 321:501-507, 1989

• 33) 内山真一郎:チクロピジン. 抗血小板薬の作用と特徴. Up Date抗血小板療法. 現代医療 25:3279-3285, 1993

• 34) Defreyn, G., Gachet, C., Savi, P. et al.:Ticlopidine and clopidogrel (SR25990C) selectively neutralize ADP inhibition of PGEI activated platelet adenylate cyclase in rats and in rabbits. Thromb. Haemost. 65:186-190, 1991

• 35) Mills, D. C. B., Puri, R., Hu, C. J. et al.:Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler. Thromb. 12:430-436, 1992

• 36) Uchiyama, S., Yamazaki, M., Maruyama, S. et al.:Shear-induced platelet aggregation and its inhibition by antiplatelet agents in cerebral ischemia. Clin. Hemorheol. 13:623-636, 1993

• 37) Uchiyama, S., Yamazaki, M., Maruyama, S. et al.:Shear-induced platelet aggregation in cerebral ischemia. Stroke 25:1547-1551, 1994
  pubmed

• 38) Vargaftig, B. B., Chara, M., Benveniste, J.:Present concept on the mechanism of platelet aggregation. Biochem. Pharmacol. 30:263-271, 1981

• 39) 内山真一郎:虚血性脳血管障害の二次予防. 特集:虚血性脳血管障害の基礎と臨床-最近の進歩-. 最新医学 49:1574-1582, 1994

• 40) 風間睦美, 安部英:経口抗凝血薬療法ガイドライン. 血液と脈管 16:431-440, 1985

• 41) Stein, B., Fuster, V., Halperin, J. L. et al.:Antithrombotic therapy in cardiac disease. An emergency approach based on pathogenesis and risk. Circulation 80:1501-1513, 1989
  pubmed

• 42) 内山真一郎:抗血栓薬内服者の外来での凝血学的検査. 日本医事新報 3560:135-136, 1992

• 43) 上塚芳郎, 細田瑳一, 青崎正彦ほか:経口抗凝血薬療法におけるトロンボテスト (%) とプロトロンビン時間 (INR) の臨床的意義について. 血栓止血誌 3:123-130, 1992

• 44) Stroke Prevention in Atrial Fibrillation Investigators:I. Clinical features of patients at risk. Ann. Intern. Med. 116:6-12, 1992

• 45) Stroke Prevention in Atrial Fibrillation Investigators:II. Echocardiographic features of patients at risk. Ann. Intern. Med. 116:6-12, 1992
  pubmed

• 46) Sherman, D. G.:Stroke prevention trials in atrial fibrillation. Cerebrovasc. Dis. 2 (Suppl. 1):14-17, 1992

• 47) The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators:The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323:1505-1511, 1990
  pubmed

• 48) Adams, H. P. Jr., Brott, T. G., Crowell, R. M. et al.:Guideline for the management of patients with acute ischemic stroke. A statement for health care professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 25:1901-1914, 1994

• 49) Massey, E. W., Biller, J., Davis, J. N. et al.:Heparinoid Org (0172 in stroke. A study of large dose infusions in acute or progressing stroke. Stroke 21:1289-1292, 1990
  pubmed

• 50) Sandercock, P., Willems, H.:Medical treatment for acute ischemic stroke. Lancet 339:537-539, 1992

• 51) Brott, T. G., Haley, E. C. Jr., Levy, D. E. et al.:Urgent therapy for stroke. Part I. Pilot sutdy of tissue plasminogen acitvator administered within 90 minutes. Stroke 23:632-640, 1992

• 52) Haley E. C. Jr., Levy, D. E., Brott, T. G. et al.:Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23:641-645, 1992
  pubmed

• 53) 大友英一, 東儀英夫, 平井俊作ほか:脳血栓症に対する組織プラスミノゲンアクチベーター (AK-124) の臨床上の有用性-多施設二重盲検によるウロキナーゼとの比較試験-. 薬理と治療 16:3775-3821, 1988

• 54) 大友英一, 東儀英夫, 平井俊作ほか:脳血栓症に対する組織プラスミノゲンアクチベーター (AK-124) の臨床上の有用性-多施設二重盲検によるプラセボとの比較試験-. 臨床と研究 69:1589-1610, 1992

• 55) 安部英, 赫彰郎, 東儀英夫ほか:脳血栓症に対するSM-9527 (t-PA) 静脈内投与の臨床的有用性の検討-ウロキナーゼを対照とした二重盲検比較試験-. Clin. Eval. 18:39-63, 1990

• 56) Counsell, C. E, Fraser, H., Sandercock, P. A. G.:Archie Cochrane's challenge:can periodically updated reviews of all randamised controlled trial relevant to neurology and neurosurgery be produced?J. Neurol. Neurosurg. Psychiatry. 57:529-533, 1994

• 57) Hacke, W., Kaste, M., Fieschi, C. et al.:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) . JAMA 274:1017-1025, 1995
  pubmed

• 58) The National Institute of Neurological Disordars and Stroke t-PA Stroke Study Group:Tissure plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1581-1587, 1995

• 59) 大友英一, 沓沢尚之, 木暮久也ほか:脳血栓症急性期におけるOKY-046の臨床的有用性. 臨床医薬 7:353-388, 1991

• 60) 内山真一郎, 原由紀子, 丸山勝一ほか:脳血栓症患者におけるオザグレルの尿中11dehydro-TXB2と2, 3dinor-6ketoPGF1αに及ぼす影響. 第20回日本脳卒中学会総会 (抄録) No.311, 1995

• 61) Dunbabin, D., Sandercock, P.:Antiplatelet therapy in the treatment and prevention of vascular disease:some clear answers, some new questions. Platelets 5:3-12, 1994
  pubmed

• 62) Yamaguchi, T., Nishimaru, K., Minematsu, K. for the Japanese Antiplatelet Stroke Prevention Study Group.:Benefits and hazards of antiplatelet therapy in ischemic cerebrovascular diseases. 脈管学 3 4:279-285, 1994

• 63) Yamaguchi, T., Hayakawa, T., Kikuchi, H. et al.:Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc. Dis. 3:269-272, 1992

• 64) Okada, Y., Sadoshima, S., Nakane, H. et al.:Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism. Stroke 23:20-23, 1992
  pubmed

• 65) Stroke Prevention in Atrial Fibrillation Investigators:Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687-691, 1994

• 66) EAFT (European Atrial Fibrillation Trial) Study Group:Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342:1255-1262, 1993
  pubmed

P.284 掲載の参考文献

• 1) NINCDS Committee:Classification of cerebrovascular diseases III. Stroke 21:637-676, 1990

• 2) 厚生省循環器病委託研究班:動脈硬化性疾患の定義および診断基準に関する研究. 平成元年度厚生省循環器病委託費による研究報告集, 1989, p.80.

• 3) Millikan, C. H., Siekert, R. G.:Studies in cerebrovascular disease. I. The syndrome of intermittent insufficiency of the basilar arterial system. Pro. Staff Meetings Mayo Clin. 30:61-68, 1955

• 4) 山下一也, 小林祥泰:内頸動脈系TIAの成因と臨床. 日本臨床別冊CT・MRI時代の脳卒中学 662 (増刊1):948-953, 1994

• 5) 小林祥泰:TIAの診断と治療. Medicina 27:2434-2435, 1990

• 6) 小林祥泰:一過性脳虚血発作. 診断と治療 75:1958-1962, 1987

• 7) Baquis, G. D., Pessin, M., Scott, R. M.:Limb shaking-A carotid TIA. Stroke 16:444-448, 1985
  pubmed

• 8) Nagao, T., Sadoshima, S., Ibayashi, S. et al.:Increase in extracranial atherosclerotic carotid lesions in patients with brain ischemia in Japan:An angiographic study. Stroke 25:766-770, 1994
  pubmed

• 9) Lechat, P., Mas, J. L, Lascault, G. et al.:Prevalence of patent foramen ovale in patients with stroke. N. Engl. J. Med. 318:1148-1152, 1988
  pubmed

• 10) Hanna, J. P., Sun, J. P., Furlan, A. J. et al.:Patent foramen ovale and brain infarct:echocardiographic predictictors, recurrence, and prevention. Stroke 25:782-786, 1994
  pubmed

• 11) Urakami, K., Igo, M., Takahashi, K.:An epidemiological study of cerebrovascular disease in Western Japan:with special reference to transient ischemic attacks. Stroke 18:396-401, 1987

• 12) Ueda, K., Kiyohara, Y., Hasuno, Y. et al.:Transient ischemic attacks in a Japanese community, Hisayama, Japan. Stroke 18:844-848, 1987

• 13) 岡田和悟, 山形真吾, 福田稔ほか:高齢化地域における3年間の脳卒中発症調査. 日本老年医学会雑誌 32:39-46, 1995

• 14) 伊藤栄一:一過性脳虚血発作 (TIA) の最近の経過と予後. 神経内科治療 8:367-372, 1991
  Medical*Online

• 15) Whisnant, J. P., Matsumoto, N., Elveback, L. R.:Transient cerebral ischemic attacks in a community:Rochester, Minnesota, 1955 through 1969. Mayo Clin. Proc. 48:194-198, 1973

• 16) Denis, M., Bamford, J., Sandercock, P. et al.:Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 21:848-853, 1990

• 17) Caplan, L. R.:TIAs:We need to return to the question, "what is wrong with Mr. Jones?" Neurology 38:791-793, 1988

• 18) 大友栄一:脳血管障害における最近の諸問題. 臨床科学 25:4-10, 1989

• 19) Toole, J. F.:The Willis lecture:transient ischemic attacks, scientific method, and new realities. Stroke 22:99-104, 1991
  pubmed

• 20) Awad, I., Modic, M., Little, J. R. et al.:Focal parenchymal lesions in transient ischemic attacks:correlation of computed tomography and magnetic resonance imaging. Stroke 17:399-403, 1986
  pubmed

• 21) Crepin, L. T., Majdalani, A., Gautier, J. C.:Comparison between X-ray computed tomography and magnetic resonance imaging after transient ischemic accidents. Rev. Neurol. 147:737-739, 1991

• 22) Baron, J. C., Bousser, M. G., Rey, A. et al.:Reversal of focal"misery perfusion syndrome"by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. Stroke 12:454-459, 1981
  pubmed

• 23) Powers, W. J. et al.:Extracrania-ntracranial bypass surgery:Hemodynamic and metabolic effects. Neurology 34:1168-1174, 1984

• 24) 田中真, 平井俊策, 近藤進:X線CTによって描出し得ない脳血管障害のpositron emission tomographyによる検討. 脳卒中 11:491-499, 1989

• 25) Hartmann, A.:Prolonged disturbance of regional cerebral blood flow in transient ischemic attacks. Stroke 16:932-939, 1985
  pubmed

• 26) Knop, J., Thie, A., Fuchs, C. et al.:99mTc-HMPAO with acetazolamide challenge to detect hemodynamic compromise in occlusive cerebrovascular disease. Stroke 23:1733-1742, 1992
  pubmed

• 27) Patrono, C.:Aspirin as an antiplatelet drug. N. Engl. J. Med. 330:1287-1294, 1994
  pubmed

• 28) 西丸雄也:抗凝血薬 抗血小板薬と超急性期治療. 臨床成人病 25:197-201, 1995

• 29) 村上元孝, 豊倉康夫, 尾前照雄ほか:一過性脳虚血発作 (TIA) に対するチクロピジンおよびアスピリンの効果. 診断と治療 74:2255-2274, 1986

• 30) Albers, G. W.:Role of ticlopidine for prevention of stroke. Stroke 23:912-916, 1992
  pubmed

• 31) DiMinno, G., Cerbone, A. M., Mattioli, P. L. et al.:Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J. Clin. Invest. 75:328-338, 1985

• 32) 内山真一郎, 堤由紀子, 長山隆ほか:脳虚血における少量アスピリン・チクロピジン併用療法の抗血小板効果. 臨床神経 29:579-583, 1989

• 33) 大友英一, 田代邦雄, 東儀英夫ほか:酒石酸イフェンプロジル (セロクラール(R)) の脳梗塞再発予防効果-塩酸チクロピジンを対照とした多施設における Open Trial. 薬理と治療 22:3227-3245, 1994
  Medical*Online

• 34) CALTスタディグループ:虚血性脳血管障害に対する dilazep, aspirin 併用群と aspirin 単独群の長期投与 (3年間投与) の効果比較検討. 神経内科治療 8:459-467, 1991
  Medical*Online

• 35) 岡田和悟, 山形真吾, 渡部雄治ほか:脳梗塞後遺症ならびに慢性脳循環不全症に対するニセルゴリンの臨床効果と血小板凝集能の検討. 新薬と臨床 44:419-423, 1995
  Medical*Online

• 36) The EPIC Investigators:Use of a monoclonal antibody directed aganist the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330:956-961, 1994

• 37) Hirsh, J., Poller, L:The International Normalized Ratio. A rch. Intern. Med. 154:282-288, 1994

• 38) North America Symptomatic Carotid Endoarterectomy Trial Collabrators:Beneficial effect of carotid endoarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. 325:445-453, 1991

• 39) European carotid surgery trialist:s collaborative group:MRC European carotid surgery trial:interium results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 337:1235-1243, 1991

• 40) Mayberg, M. R., Wilson, S. E., Yatsu, F. et al.:Carotid endoarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 266:3289-3294, 1991

• 41) Komiya, T., Kudo, M., Urabe, T. et al.:Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease:assessment by platelet aggregation testing. Stroke 25:2337-2342, 1994
  pubmed

• 42) Helgason, C. M., Bolin, K. M., Hoff, J. A. et al.:Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25:2331-2336, 1994
  pubmed

• 43) Fon, E. A., Mackey, A., Cote, R. et al.:Hemostatic makers in acute transient ischemic attacks. Stroke 25:282-286, 1994

• 44) Levine, H. J.:Hemorrhagic complication of long term anticoagulation. Stroke 17:111-116, 1986

• 45) Antiplatelet trialists:collaboration:Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. J. 296:320-331, 1988

• 46) Genton, E., Barneu, H. J. M., Fields, W. S. et al.:Report of the joint committee for stroke resources, XIV. Cerebral ischemia:The role of thrombosis and antithrombotic therapy. Stroke 8:150-175, 1977

• 47) The Canadian Cooperative Study Group:Arandomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 299:53-59, 1978

• 48) Sze, P. C., Reitman, D., Pincus, M. M. et al.:Antiplatelet agents in the secondary prevention of stroke:meta-analysis of the randomized control trials. Stroke 19:436-442, 1988

• 49) Guiraud, C. B., Rascol, A., David, J. et al.:Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettarires. Rev. Neurol. 138:367-385, 1982

• 50) Candelise, L., Landi, G., Perrone, P. et al.:Arandomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 13:175-179, 1982

• 51) Bousser, M. G., Eschwege, E., Haguenau, M. et al.:"AICLA"controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14:5-14, 1983
  pubmed

• 52) Sorensen, P. S., Pedersen, H., Marquardsen, J. et al.:Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish Cooperative Study. Stroke 14:15-22, 1983
  pubmed

• 53) A Swedish Cooperative Study:High-dose acetylsalicylic acid after cerebral infarction. Stroke 18:325-334, 1987
  pubmed

• 54) The ESPS Study Group:The European stroke prevention study (ESPS) Principal end-point. Lancet 8572:1351-1354, 1987

• 55) UK-TIA study group:United Kingdom transient ischemic attack (UK-TIA) aspirin trial:interim results. Br. Med. J. 296:316-320, 1988

• 56) UK-TIA study group:The United Kingdom transient ischemic attack (UK-TIA) aspirin trial:final results. J. Neurol. Neurosurg Psychiatry 54:1044-1054, 1991

• 57) The SALT Collaborative group:Swedish aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 338:1345-1349, 1991

• 58) The Dutch TIA Trial Group:Acomparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325:1261-1266, 1991
  pubmed

• 59) Antiplatelet trialists:collaboration:Collaborative overview of randomised trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106, 1994

• 60) Warlow, C.:Secondary prevention of stroke. Lancet 339:724-727, 1992
  pubmed

• 61) Becker, R. C., Ansell, J.:Antithrombotic therapy-an abbreviated reference for clinicians. Arch. Intern. Med. 155:149-161. 1995
  pubmed

• 62) Gent, M., Blakely, J. A., Easton, J. D. et al.:The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1:1215-1220, 1989
  pubmed

• 63) Hass, W. K., Easton, J. D., Adams, H. P. et al.:Arandomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N. Engl. J. Med. 321:501-507. 1989

• 64) 伊藤栄一:脳梗塞再発予防と改善薬. 循環科学 10:392, 1990

• 65) 東海林幹, 針谷康夫, 岡本幸市ほか:虚血性脳血管障害における再発例の検討-主に抗血小板薬使用例の分析. 脳卒中 9:246-252, 1987

• 66) CALT StudyII Group:虚血性脳血管障害に対する塩酸ジラゼプ単独とアスピリン少量単独群での長期投与による再発防止効果の比較検討 (第3報) . 第17回日本脳卒中学会抄録. 1992

• 67) Yamaguchi, T., Nishimaru, K., Minematsu, K.:Benefits and hazards of antiplatelet therapy in ischemic cerebrovascular disease. J. Jan. Coll. Angiol. 34:279-285, 1994

• 68) Cerebral Embolism Task Force:Cardiogenic brain embolism. Arch. Neurol. 43:71-84, 1986
  pubmed

• 69) Petersen, P., Godtfredsen, J., Boysen, G. et al.:Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation:The Copenhagen AFASK study. Lancet 1 (8631):175-179, 1989
  pubmed

• 70) The Boston Area Anticoagulation Trial for Atrial Fibrillation lnvestigators:The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323:1505-1511, 1990
  pubmed

• 71) The Stroke Prevention in Atrial Fibrillation Investigators:The stroke prevention in atrial fibrillation study:final results. Circulation 84:527-539, 1991

• 72) Connoly, S., Laupacis, A., Gent, M.:Canadian atrial fibrillation anticoagulation (CAFA) study. J. Am. Coll. Cardiol. 18:349-355, 1991

• 73) Ezekowitz, M., Bridgers, S., James, K. et al.:Veterans Affairs cooperative study of warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N. Engl. J. Med. 327:1406-1412, 1992

• 74) EAFT (European Atrial Fibrillation Trial) Study Group:Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342:1255-1262, 1993
  pubmed

• 75) Stroke Prevention in Atrial Fibrillation Investigators:Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:Stroke prevention in Atrial Fibrillation II study. Lancet 343:687-691, 1994

• 76) Atrial Fibrillation Investigators:Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.-Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154:1449-1457, 1994

• 77) Camm, A. J., Murgatroyd, F. D.:Nonpharmaceutical Treatment of Atrial Fibrillation. In:Atrial Fibrillation (The Bakken Reserch Center Series vol. 8) (eds:Kulbertus, H. E., Wellens, H. J. J., Bourgeois, I. M. G. P. et al.) . Futura Publishing Company Inc, 1994, p. 125-148

P.297 掲載の参考文献

• 1) 外科止血ハンドブック. 現代医療社, 1985

• 2) The Basic Science of Vascular Surgery;13. Drugs in Vascular Surgery. Futura Publishing Co., NY., 1988

• 3) 上林純一, 森武貞ほか:外科領域における抗血小板薬. 臨床科学 28 (8):1992

• 4) 上林純一, 森武貞ほか:末梢動脈閉塞症での薬物療法. 現代医療 24 (10):1992

• 5) Salzman, E. W. et al.:Hemostasis and Thrombosis. Basic Principles and Clinical Practice. J. B. Lippincott Co. NY., 1994

P.305 掲載の参考文献

• 1) Brandjes, D. P. M., Heijboer, H., Buller, H. R. et al.:Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N. Engl. J. Med. 327:1485-1489, 1992

• 2) Salzman, E. W., Deykin, D., Shapiro, R. M. et al.:Management of heparin therapy:controlled Prospective trial. N. Engl. M. Med. 292:1049-1050, 1975

• 3) Glazier, R. L., Crowell, E. B. et al.:Randomized prospective trial of continuous vs intermittent heparin therapy. J. Am. Med. Assoc. 236:1365-1367, 1976

• 4) Gallus, A., Jackaman, J., Tillett, J. et al.:Safety and efficacy of warfarin started early after submassive venous thrombosis of pulmonary embolism. Lancet ii:1293-1296, 1986

• 5) Hull, R. D., Raskob, G. E., Rosenbloom, D. et al.:Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med. 322:1260-1264, 1990
  pubmed

• 6) Prandoni, P., Leusing, A. W., Buller, H. R. et al.:Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal venous thrombosis. Lancet 339:441-445, 1992

• 7) Hull, R. D., Raskob, G. E., Pineo, G. F. et al.:Subcutaneous low-molecular weight heparin compaired with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326:975-982, 1992

• 8) Research committee of British thoracic society:Optimum duration of anticoagulation for deepvein thrombosis and pulmonary embolism. Lancet 340:873-876, 1992
  pubmed

• 9) Antiplatelet Trialists:Collaboration:Collaborative overview of randomized traials of antiplatelet therapy-III:Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308:235-246, 1994

• 10) Rogers, L. Q., Lutcher, C. L. et al.:Streptokinase therapy for deep vein thrombosis:acomprehensive review of the English literature. Am. J. Med. 88:389-395, 1990

• 11) Goldhaber, S. Z., Buring, J. E., Lipnick, R. J. et al.:Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep vein thrombosis. Am. J. Med. 76:393-397, 1984

• 12) Goldhaber, S. Z., Polak, J. F., Feldstein, M. L. et al.:Efficacy and safety of repeated boluses of urokinase in the treatment of deep vein thrombosis. Am. J. Cardiol. 73:75-79, 1994
  pubmed

• 13) Goldhaber, S. Z., Meyerouitz, M. F., Green, D. et al.:Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am. J. Med. 88:235-240, 1990

P.319 掲載の参考文献

• 1) 石川浩一:糖尿病性壊疽治療の最前線, 序. 血管外科 12:1, 1993

• 2) Matsuda, A.:Arteriosclerosis obliterans in Japanese diabetic patients. Tohoku J. Exp. Med. 141 (Suppl):569-573, 1983

• 3) 村瀬敏郎, 赤沼安夫:糖尿病患者における下肢末梢血管障害合併頻度-他施設共同調査研究. 糖尿病 36 (Suppl. 1), 1993

• 4) Kannel, W. B., McGee, D. L.:Diabetes and cardiovascular disease:The Framingham study. JAMA 241:2035-2038, 1979
  pubmed

• 5) 安原洋, 重松宏:糖尿病を合併した下肢閉塞性動脈硬化症症例の検討. 脈管学 33:573-575, 1993

• 6) 重松宏, 安田慶秀, 田辺達三:重症虚血肢をめぐる諸問題-日本の現状と診断基準. Ther. Res. 13:4099-4109, 1992

• 7) Alvarez, O. M., Gilson, G., Auletta, M. J.:Local aspects of diabetic foot ulcer care:Assessment, dressings, and topical agents. in:Diabetic Foot (5th ed.), Mosby Year Book, 1993, p. 259-279

• 8) 平井正文:糖尿病性壊疽の診断. 血管外科 12:27-33, 1993

• 9) Second European Consensus Document on Chronic Critical Leg Ischemia. Eur. J. Vasc. Surg 6 (Suppl. A):1-32, 1992

• 10) LoGerfo, F. W. et al.:Trends in the care of the diabetic foot-Expanded role of arterial reconstruction. Arch. Surg. 127:617, 1992
  pubmed

• 11) Quayle, J. B.:Diabetic autonomic neuropathy in patients with vascular disease. Br. J. Surg. 65:305-307, 1978
  pubmed

• 12) 大西克幸:DM gangrene のその他の治療法. 血管外科 12:178-181, 1993

• 13) Leslie, C. A., Sapico, F. L, Ginunas, V. J. et al.:Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 11:111-115, 1988
  pubmed

• 14) Wattel, F. et al.:Hyperbaric oxygen therapy in chronic vascular wound management. Angiology 41:59-65, 1990
  pubmed

• 15) Hunt, J. A.:Foot infections in diabetes are rarely due to a single microorganism. Diabet. Med. 9:749-752, 1992
  pubmed

• 16) Chowdary, R. P., Celani, V. J., Goodreau, J. J. et al.:Free-tissue transfers for limb salvage utilizing in sitza saphenous vein bypass conduit as the inflow. Plast. Reconstr. Surg. 87:529-535, 1991
  pubmed

• 17) Greenwald, L. L.:Free vasculized tissue transfer for limb salvage in peripheral vascular disease. Ann. Vasc. Szarg. 4:244-254, 1990

• 18) Knighton, D. R., Ciresi, K., Fiegel, V. D. et al.:Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg. Gynecol. Obstet. 170:56-60, 1990
  pubmed

• 19) Knighton, D. R., Fylling, C. P., Fiegel, V. D. et al.:Amputation prevention in an independently reviewed at-risk diabetic population using a comprehensive wound care protocol. Ann. J. Surg. 160:466-471, 1990

• 20) Knighton, D. R., Fiegel, V. D.:Growth factors and repair of diabetic wounds. In:Diabetic Foot (5th ed.), Mosby Year Book, 1993, p.247-257

P.332 掲載の参考文献

• 1) DeLee, L. B.:Acase of fatal hemorrhagic diathesis with premature detachment of the placenta. Am. J. Obstet. 44:785-791, 1901

• 2) Nemerson, Y.:The tissue factor pathway of blood coagulation. Semin. Hematol. 29:170-176, 1992
  pubmed

• 3) Salgado, A., Boveda, J. L, Monaterio, J. et al.:Inflammatory mediators and their influence on hemostasis. Haemostasis 24:132-138, 1994

• 4) Okajima, K., Wang, Y. P. et al.:Role of leukocytes in the activation of intravascular coagulation in patients with septicemia. Am. J. Hematol. 36:265-271, 1991

• 5) Ohlsson, K.:The extracellular release of granulocyte collagenase and elastase during phagocytosis and inflammatory process. Scand. J. Haematol. 19:145-161, 1977

• 6) Wachtfogel, Y. T., Pixley, R. A., Kucich, U. et al.:Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67:1731-1737, 1986
  pubmed

• 7) Schapira, M, Despland, E., Scott, C. F. et al:Purified human kallikrein aggregates human blood neutrophils. J. Clin. Invest. 69:1199-1201, 1982
  pubmed

• 8) Campbell, E. J., Senior, R. M., McDonald, J. A. et al.:Proteolysis by neutrophils. J. Clin. Invest. 70:845-852, 1982
  pubmed

• 9) Mulligan, M. S., Varani, J., Dame, M. K. et al.:Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Inest. 70:845-852, 1982

• 10) Okajima, K., Fujise, R., Motosato, Y. et al.:Plasma levels of granulocyte elastase-alpha-1-proteinase inhibitor complex in patients with disseminated intravascular coagulation:Patho-physiological implications. Am. J. Hematol. 47:82-88, 1994

• 11) Aoki, N., Saito, H., Kamiya, T. et al.:Congenital deficiency of alpha-2-plasmin inhibitor associated with severe hemorrhagic tendency. J. Clin. Invest. 63:877-883, 1979
  pubmed

• 12) Avvisati, G., ten Cate, J. W., Struk, A. et al.:Acquired alpha-2-plasmin inhibitor deficiency in acute promeylocytic leukemia. Br. J. Haematol. 70:43-48, 1988

• 13) Okajima, K., Koga, S., Okabe, H. et al.:Characterization of fibrinolytic state by measuring stable crosslinked fibrin degradation products in disseminated intravascular coagulation associated with acute promyelocytic leukemia. . 4cta Haemato 1. 81:15-18, 1989

• 14) Okajima, K., Soe, G., Kohno, I. et al.:Direct evidence for systemic fibrinogenolysis in patients with acquired alpha-2-plasmin inhibitor deficiency. Am. J. Hematol. 45:16-24, 1994
  pubmed

• 15) Okajima, K., Kohno, I., Tsuruta, J. et al.:Direct evidence for systemic fibrinogenolysis in a patients with metastatic prostatic cancer. Thromb. Res. 66:717-727, 1992

• 16) Okajima, K., Abe, H., Binder, B. R.:Endothelial cell injury induced by plasmin in vitro. J. Lab. Clin. Med. 126:377-384, 1995
  pubmed

• 17) Bone, R. C.:Sepsis and coagulation. An important link. Chest 101:594-602, 1994

• 18) Matsuda, M., Wakabayashi, K., Aoki, N. et al.:alpha-2-Plasmin inhibitor is among acute phase reactants. Thromb. Res. 17:527-532, 1980
  pubmed

• 19) Marks, J. D., Marks, C. B., Luce, J. M. et al.:Plasma tumor necrosis factor in patents with septic shock. Am. Rev. Respir. Dis. 141:94-100, 1990

• 20) Newman, W., Beall, L. D., Carson, C. W. et al.:Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J. Immunol. 150:644-651, 1993
  pubmed

• 21) Okajima, K., Uchiba, M., Murakami, K. et al.:Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation. Shock 3 (Suppl.):56, 1995

• 22) Abe, H., Okajima, K., Okabe, H. et al.:Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J. Lab. Clin. Med. 123:874-881, 1994
  pubmed

• 23) Rodeghiero, G., Castman, L., Gugliotta, M. et al.:Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. Thromb. Res. 69:377-385, 1993

• 24) Yamauchi, T., Umeda, F., Inoguchi, T. et al.:Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem. Biophys. Res. Commun. 163:1404-1411, 1989
  pubmed

• 25) Horie, S., Ishii, H., Kazama, M.:Heparin-like glycosaminoglycans is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb. Res. 59:895-904, 1990

• 26) Uchiba, M., Okajima, K., Murakami, K. et al.:Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma levels of 6-keto-PGFlalpha in rats. Thromb. Res. 80:201-208, 1995

• 27) Uchiba, M., Okajima, K., Murakami, K. et al.:Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am. J. Physiol 1996 (in press)

• 28) Okajima, K., Uchiba, M., Murakami, K.:Antithrombin replacement in DIC and MOF. In:Yearbook of Intensive Care and Emergency Medicine 1995 (ed:Vincent, J. L.), Heiderberg, Springer-Verlag, 1995, p. 457-464

• 29) Murakami, K., Okajima, K., Uchiba, M. et al.:Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes. Crit. Care Med. 1996 (in press)

• 30) Uchiba, M., Okajima, K., Abe, H. et al.:Effect of nafamostat mesilate, a synthetic protease inhibitor, on the extrinsic pathway of coagulation. In:DIC:Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. (eds:Muller-Berghaus, G. M. et al.), Amsterdam, Elsevier Science Publishers, 1993, p.243-251

• 31) Uchiba, M., Okajima, K., Abe, H. et al.:Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb. Res. 74:155-161, 1994
  pubmed

• 32) Okajima, K., Uchiba, M., Murakami, K.:Nafamostat mesilate.Cardiovasc. Drugs Rev. 13:51-65, 1995

• 33) Okajima, K., Koga, S., Kaji, M. et al.:Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb. Haemost. 63:48-53, 1990
  pubmed

• 34) Okajima, K., Imamura, S., Koga, S. et al.:Treatment of patients with disseminated intravascular coagulation by protein C. Am. J. Hematol. 33:277-278, 1990

• 35) Taylor, F. B. Jr., Chang, A., Esmon, C. T. et al.:Protin C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J. Clin. Invest. 79:918-925, 1987

• 36) Murakami, K., Okajima, K., Uchiba, M. et al.:Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996 (in press)

• 37) 小林紀夫, 前川正, 青木延雄ほか:DICに対するアンチトロンビンIII濃縮製剤の治療効果に関する多施設臨床治験成績. 臨床医薬 1:773-800, 1985
  Medical*Online

• 38) 小林宏行, 河合伸, 押谷浩ほか:感染症由来DICに対するアンチトロンビンIII濃縮製剤の治療効果に関する研究. 感染症学雑誌 59:1121-1134, 1985

• 39) 真木正博, 相馬広明, 寺尾俊彦ほか:産科的DICに対するATIII濃縮製剤の臨床評価. 産婦人科治療 53:471-482, 1986

• 40) Vinazzer, H.:Therapeutic use of antithrombin m in shock and disseminated intravascular coagulation. Semin. Thromb. Hemost. 15:347-352, 1989

• 41) Fourrier, F., Chopin, C., Huart, J-J. et al.:Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 140:882-888, 1993

• 42) 神前五郎, 上林純一, 平山亮夫ほか:DICに対するFOYの治療効果に関する研究. 医学のあゆみ 124:144-154, 1983

• 43) Shibata, A., Takahashi, H., Aoki, N. et al.:Nafamostat mesilate as a therapy for disseminated intravascular coagulation:A well-controlled multicenter comparative study. Thromb. Haemost. 65:371 (abstr.), 1991

• 44) 桜川信男, 長谷川淳, 真木正博ほか:汎発性血管内血液凝固症 (DIC) に対する低分子ヘパリン (FR-860) の臨床評価. 臨床医薬 8:423-452, 1992

• 45) Avvisati, G., ten Cate, J. W., Buller, H. et al.:Tranexamic acid for control of haemorrhage in acute promyelocytic leukemia. Lancet ii:122-124, 1989

P.341 掲載の参考文献

• 1) Remuzzi, G.:Thrombotic thrombocytope-nic purpura and allied disorders. Thrombosis and hemostasis XI th congress, 1987, p.673-708

• 2) Lian, E. C.:Pathogenesis of thrombotic thrombocytopenic purpura. Semin. Hematol. 24:82-100, 1987
  pubmed

• 3) 和田英夫, 南信行, 白川茂ほか:TTP (血栓性血小板減少性紫斑病) 病態-各種の指標から-, サイトカイン. 日本臨床 51:151-154, 1993

• 4) Forsyth, K. D., Simpson, A. C., Fitzpatrick, M. M. et al.:Neutrophil-mediated endothelial injury in hemolytic uremic syndrome. Lancet II:411-414, 1989

• 5) Butcher, E. C.:Leukocyte-endothelial cell recognition:three (or more) steps to specificity and diversity. Cell 67:1033-1036, 1991

• 6) 藤元哲郎, 藤村欣吾:P-セレクチン (GMP-140) . Annual Review 血液. 1993, p.184-193

• 7) Moake, J. L.:Haemolytic-uraemic syndrome:basic science. Lancet 343:393-397, 1994
  pubmed

• 8) 服部晃, 帯刀亘 (日本TTP研究班):TTP (血栓性血小板減少性紫斑病) 治療の変遷と効果. 日本臨床 51:178-183, 1993

• 9) 伊藤和彦, 服部晃, 広沢信作ほか:TTP (血栓性血小板減少性紫斑病) 血漿輸注, 血漿交換療法のプロトコール. 日本臨床 51:184-186, 1993

• 10) 上田恭典:HUS (溶血性尿毒症症候群) 治療. 日本臨床 51:215-221, 1993

P.348 掲載の参考文献

• 1) Harris, E. N., Gharavi, A. E., Boey, M. L. et al.:Anti-cardiolipin antibodies:detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet ii:1211-1214, 1983

• 2) Hughes, G. R. V., Harris, E. N., Gharavi, A. E.:The anticardiolipin syndrome. J. Rheumatol. 13:486-489, 1986

• 3) Asherson, R. A., Khamashta, M. A., Ordi-Ros, J. et al.:The "primary" anti-phospholipid syndrome:major clinical and serological features. Medicine 68:366-374, 1989
  pubmed

• 4) McNeil, H. P., Simpton, R. J., Chesterman, C. N. et al.:Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation:β2-glycoprotein I (apolipoprotein H) . Proc. Natl. Acad. Sci. USA 87:4120-4124, 1990

• 5) Matsuura, E., Igarashi, Y., Fujimoto, M. et al.:Anticardiolipin cofactor (s) and differential diagnosis of autoimmune disease. Lancet 336:177-178, 1990
  pubmed

• 6) Kato, H., Enjyoji, K.:Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I:presence of five sushi domains. Biochemistry 30:11687-11694, 1991

• 7) Asherson, R. A.:The catastrophic antiphospholipid syndrome. J. Rheumatol. 19:508-512, 1992

• 8) Silveira, L. H., Hubble, C. L., Jara, L. J. et al.:Prevention of anticardiolipin antibody related pregnancy losses with prednisone and aspirin. Am. J. Med. 93:403-411, 1992
  pubmed

• 9) Kaaja, R., Julkunen, H., Ammala, P. et al.:Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obsted. Gynecol. Scand. 72:63-66, 1993
  pubmed

• 10) 医療薬日本医薬品集1994年8月版. 日本医薬情報センター編, 薬業時報社, 東京, 1994

• 11) Piette, J. C.:Editorial:prevention of reccurent thrombosis in the antiphospholipid syndrome. Lupus 3:73-74, 1994

• 12) Rivier, G., Herranz, M. T., Khamashta, M. A. et al.:Thrombosis and antiphospholipid syndrome:apreliminary assessment of three antithrombotic treatment. Lupzas 3:85-90, 1994

• 13) Vlachoyiannopoulos, P. G., Tsiakou, E., Chalevelakis, G. et al.:Antiphospholipid syndrome:clinical and therapeutic aspects. Lupus 3:91-96, 1994
  pubmed

P.357 掲載の参考文献

• 1) Yazici, H., Barnes, C. G.:Practical treatment recomendations for pharmacotherapy of Behcet's syndrome. Drugs 42:796-804, 1991

• 2) 舟内正憲, 福間尚文, 木佐森茂樹ほか:Urokinase の大量投与が著効を示したベーチェット病の1例. 内科 52:1167--1170, 1983

• 3) 浦野哲盟, 坂口周吉, 神谷隆ほか:動静脈血栓症. 臨床血液 25:1036-1042, 1984

• 4) 長井英夫, 山口昌夫:ベラプロストナトリウム投与が有効であった肺塞栓症を合併した慢性期深部静脈血栓症の1例. 新薬と臨床 44:92-94, 1995
  Medical*Online

• 5) 竹内明輝, 川村洋和, 善平朝俊ほか:ベーチェット病の下腿潰瘍に対する経口プロスタグランディンE1剤. 炎症 3:499-500, 1983

• 6) 横内正利:抗凝固療法 血栓溶解療法. 治療薬ガイド'94 (和田攻, 大久保昭行, 永田直一ほか編), 文光堂, 1994, p.274-282

• 7) 横内正利:循環器疾患の新しい薬物療法, 抗凝血薬療法の適応とその実際. Modern Physician 11:979-984, 1991

• 8) 橋本喬史, 富永淑子:BehCet病. 臨床医 7:1580-1581, 1981

• 9) 富永淑子:ベーチェット病の血栓性静脈炎に関する研究.脈管学 25:43-49, 1985

P.366 掲載の参考文献

• 1) Antiplatelet Trialists:Collaboration:Collaborative overview of randomized trials of antiplatelet therapy I:prevention of death, myocardial infarction, stroke by prolonged trials of antiplatelet therapy in various categories of patients. BMJ 308:81-105, 1994
  pubmed

• 2) Steering Committee of the Physicians:Health Study Research Group:Final report on the aspirin component of the ongoing physicians:health study. N. Engl. J. Med. 321:129-135, 1989

• 3) Peto, R., Gray, R., Collins, R. et al.:Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296:313-316, 1988
  pubmed

• 4) Boston Collaborative Drug Surveillance Group:Regular aspirin intake and myocardial infarction. BMJ 1:440-443, 1974

• 5) Manson, J. E., Stampfer, M. J., Colditz, G. A. et al.:A prospective study of aspirin and primary prevention of cardiovascular disease in women. JAMA 266:521-527, 1991
  pubmed

• 6) Paganini-Hill, A., Chao, A., Ross, R. K. et al.:Aspirin use and chronic diseases:acohort of the elderly. BMJ 299:1247-1250, 1989

• 7) Hammond, E. C., Garfinkel, L.:Aspirin and coronary heart disease. Findings of a prospective study. BMJ 2:269-271, 1975
  pubmed

• 8) MacMahon, S., Peto, R., Cutler, J. et al.:Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure:prospective observational studies corrected for the regression diltion bias. Lancet 335:765-774, 1990
  pubmed

• 9) Collins, R., Peto, R., MacMahon, S. et al.:Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure:overview of randomised drug trials in their epidemiological context. Lancet 335:827-838, 1990
  pubmed

• 10) Early Treatment Diabetic Retinopathy Study Investigators:Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268:1292-1300, 1992

• 11) Chesebro, J. H., Opie, L. H., Fuster, V.:The recent trials for aspirin in the prevention of cardiovascular mortality. Cardiovasc. Drugs Ther. 3:353-354, 1989
  pubmed

• 12) Juul-Moller, S., Edvardsson, N., Johnmatz, B. et al.:For the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.:Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 340:1421-1425, 1992

• 13) Theroux, P., Quimet, H., McCans, J. et al.:Aspirin, heparin, or both to treat acute unstable angina. N. Engl. J. Med. 379:1105-1111, 1988

• 14) Svensson, P. J., Dahlbtick, B.:Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330:517-522, 1994

• 15) Greengard, J. S., Sun, X., Xu, X. et al.:Activated protein C resistance caused by Arg506 Gln mutation in factor Va. Lancet 343:1361-1362, 1994

• 16) Collins, R., Scrimgeour, A., Yusuf, S. et al.:Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, 0rthopedic, and urologic surgery. N. Engl. J. Med. 318:1162-1173, 1988

• 17) Rosendaal, F. R., Nurmohamed, M. T., BUIIer, H. R. et al.:Low molecular weight heparin in the prophylaxis of venous thrombosis:a meta-analysis. Thromb. Haemost. 65:927, 1991